{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T11:39:53Z","timestamp":1790422793544,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd006023.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2018,8,22]],"date-time":"2018-08-22T00:00:00Z","timestamp":1534896000000}}],"reference-count":518,"publisher":"Wiley","issue":"8","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd006023.pub3","type":"journal-article","created":{"date-parts":[[2018,8,22]],"date-time":"2018-08-22T19:46:54Z","timestamp":1534967214000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD)"],"prefix":"10.1002","volume":"2018","author":[{"given":"Marinella","family":"Ruospo","sequence":"first","affiliation":[{"name":"Diaverum; Medical Scientific Office; Lund Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suetonia C","family":"Palmer","sequence":"additional","affiliation":[{"name":"University of Otago Christchurch; Department of Medicine; 2 Riccarton Ave PO Box 4345 Christchurch New Zealand 8140"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Natale","sequence":"additional","affiliation":[{"name":"Diaverum; Medical Scientific Office; Lund Sweden"},{"name":"University of Bari; Department of Emergency and Organ Transplantation; Bari Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan C","family":"Craig","sequence":"additional","affiliation":[{"name":"The Children's Hospital at Westmead; Cochrane Kidney and Transplant, Centre for Kidney Research; Westmead NSW Australia 2145"},{"name":"Flinders University; College of Medicine and Public Health; Adelaide SA Australia 5001"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariacristina","family":"Vecchio","sequence":"additional","affiliation":[{"name":"Danone Research; RD 128 Palaiseau Cedex France 91767"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grahame J","family":"Elder","sequence":"additional","affiliation":[{"name":"Westmead Hospital; Department of Renal Medicine; Westmead NSW Australia 2145"},{"name":"Garvan Institute of Medical Research; Osteoporosis and Bone Biology Division; Darlinghurst NSW Australia 2010"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni FM","family":"Strippoli","sequence":"additional","affiliation":[{"name":"Diaverum; Medical Scientific Office; Lund Sweden"},{"name":"University of Bari; Department of Emergency and Organ Transplantation; Bari Italy"},{"name":"The Children's Hospital at Westmead; Cochrane Kidney and Transplant, Centre for Kidney Research; Westmead NSW Australia 2145"},{"name":"Diaverum Academy; Bari Italy"},{"name":"The University of Sydney; Sydney School of Public Health; Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,8,22]]},"reference":[{"issue":"3","key":"10.1002\/14651858.CD006023.pub3-BIB0001|cit1","first-page":"769","article-title":"Comparative efficacy of sevelamer hydrochloride versus calcium acetate on bone biomarkers in patients with end stage renal disease on hemodialysis","volume":"8","author":"Ahmed","year":"2014","journal-title":"Pakistan Journal of Medical & Health Sciences"},{"issue":"Sept","key":"10.1002\/14651858.CD006023.pub3-BIB0002|cit2","first-page":"557A","article-title":"Effect of sevelamer hydrochloride (PB-94) on hyperphosphatemia in Japanese hemodialysis (HD) patients [abstract no: A2940]","volume":"11","author":"Akizawa","year":"2000","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD006023.pub3-BIB0003|cit3","first-page":"755A","article-title":"Effects of PB-94 (sevelamer hydrochloride), a phosphate binder, on the treatment of hyperphosphatemia in hemodialysis patients - a randomized, open label, dose titration study of PB-94 versus caltan\u00ae tablet 500 (calcium carbonate) [abstract]","volume":"12","author":"Kinugasa","year":"2001","journal-title":"Journal of the American Society of Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub3-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/1744-9987.12068","article-title":"Randomized controlled trial of bixalomer versus sevelamer hydrochloride in hemodialysis patients with hyperphosphatemia","volume":"18","author":"Akizawa","year":"2014","journal-title":"Therapeutic Apheresis & Dialysis"},{"issue":"6","key":"10.1002\/14651858.CD006023.pub3-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/1744-9987.12461","article-title":"Bixalomer in hyperphosphatemic patients with chronic kidney disease not on dialysis: phase 3 randomized trial","volume":"20","author":"Akizawa","year":"2016","journal-title":"Therapeutic Apheresis & Dialysis"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub3-BIB0006|cit6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3968\/j.ans.1715787020120501.1001","article-title":"The effect of coadministration of nicotinamide and calcium-based phosphate binder on hyperphosphatemia in patients undergoing hemodialysis","volume":"5","author":"Allam","year":"2012","journal-title":"Advances in Natural Science"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub3-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"A152","DOI":"10.1016\/j.jval.2012.03.821","article-title":"The effect of coadminstration of nicotinamide and calcium-based phosphate binder on hyperphophatemia in patients undergoing hemodialysis [abstract]","volume":"15","author":"Allam","year":"2012","journal-title":"Value in Health"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006023.pub3-BIB0008|cit8","first-page":"i253","article-title":"Lowdose nicotinamide as an adjunctive therapy to calcium carbonate for control of hyperphosphatemia in hemodialysis patients [abstract]","volume":"28","author":"ElSharkawy","year":"2013","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"9","key":"10.1002\/14651858.CD006023.pub3-BIB0009|cit9","first-page":"976","article-title":"Ca acetate versus Ca carbonate for the control of serum phosphate in haemodialysis patients [abstract]","volume":"8","author":"Almirall","year":"1993","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub3-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1159\/000168713","article-title":"Calcium acetate versus calcium carbonate for the control of serum phosphorus in hemodialysis patients","volume":"14","author":"Almirall","year":"1994","journal-title":"American Journal of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub3-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"354","DOI":"10.5301\/jn.5000011","article-title":"Effectiveness and safety of extended-release nicotinic acid for reducing serum phosphorus in hemodialysis patients","volume":"25","author":"Aramwit","year":"2012","journal-title":"Journal of Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD006023.pub3-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1093\/ndt\/14.6.1475","article-title":"Calcium ketoglutarate versus calcium acetate for treatment of hyperphosphataemia in patients on maintenance haemodialysis: a cross-over study","volume":"14","author":"Birck","year":"1999","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD006023.pub3-BIB0013|cit13","first-page":"552A","article-title":"Calcium-ketoglutarate vs. calcium-acetate for treatment of hyperphosphatemia in patients on maintenance hemodialysis [abstract]","volume":"9","author":"Birck","year":"1998","journal-title":"Journal of the American Society of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub3-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/S0272-6386(99)70221-0","article-title":"A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients","volume":"33","author":"Bleyer","year":"1999","journal-title":"American Journal of Kidney Diseases"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD006023.pub3-BIB0015|cit15","first-page":"548a","article-title":"An open label, cross-over study of the new phosphate binder renagel in the management of hyperphosphatemia in ESRD patients [abstract]","volume":"8","author":"Bleyer","year":"1997","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD006023.pub3-BIB0016|cit16","first-page":"iv294","article-title":"Increased mortality associated with coronary artery calcium scores and calcium containing phosphate binders: long term results from a randomized controlled trial in new dialysis patients [abstract no: MO020]","volume":"21","author":"Block","year":"2006","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"5","key":"10.1002\/14651858.CD006023.pub3-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/sj.ki.5002059","article-title":"Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients","volume":"71","author":"Block","year":"2007","journal-title":"Kidney International"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub3-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1111\/j.1523-1755.2005.00600.x","article-title":"Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis","volume":"68","author":"Block","year":"2005","journal-title":"Kidney International"},{"issue":"10","key":"10.1002\/14651858.CD006023.pub3-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1093\/ndt\/gft264","article-title":"Epicardial adipose tissue predicts mortality in incident hemodialysis patients: a substudy of the Renagel in New Dialysis trial","volume":"28","author":"D'Marco","year":"2013","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1002\/14651858.CD006023.pub3-BIB0020|cit20","first-page":"735A","article-title":"Accelerated vascular calcification in diabetic patients new to hemodialysis treated with calcium salts as compared to sevelamer [abstract no: SA-PO818]","volume":"16","author":"Galassi","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"issue":"11","key":"10.1002\/14651858.CD006023.pub3-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1093\/ndt\/gfl395","article-title":"Accelerated vascular calcification and relative hypoparathyroidism in incident haemodialysis diabetic patients receiving calcium binders","volume":"21","author":"Galassi","year":"2006","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"5","key":"10.1002\/14651858.CD006023.pub3-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s40620-016-0310-9","article-title":"Epicardial adipose tissue volume increase in hemodialysis patients treated with sevelamer or calcium-based phosphate binders: a substudy of the Renagel in new dialysis trial","volume":"29","author":"Ko","year":"2016","journal-title":"Journal of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub3-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1492-7535.2004.01104.x","article-title":"Coronary and aortic calcifications in patients new to dialysis","volume":"8","author":"Spiegel","year":"2004","journal-title":"Hemodialysis International"},{"issue":"12","key":"10.1002\/14651858.CD006023.pub3-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"3568","DOI":"10.1093\/ndt\/gfm424","article-title":"Factors associated with mortality in patients new to haemodialysis","volume":"22","author":"Spiegel","year":"2007","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub3-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/j.1542-4758.2009.00387.x","article-title":"A randomized double-blind pilot study of serum phosphorus normalization in chronic kidney disease: a new paradigm for clinical outcomes studies in nephrology","volume":"13","author":"Block","year":"2009","journal-title":"Hemodialysis International"},{"issue":"8","key":"10.1002\/14651858.CD006023.pub3-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1681\/ASN.2012030223","article-title":"Effects of phosphate binders in moderate CKD","volume":"23","author":"Block","year":"2012","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub3-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1053\/j.ajkd.2017.06.017","article-title":"Deoxycholic acid, a metabolite of circulating bile acids, and coronary artery vascular calcification in CKD","volume":"71","author":"Jovanovich","year":"2018","journal-title":"American Journal of Kidney Diseases"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub3-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1053\/j.jrn.2014.02.001","article-title":"Estimation of 24-hour urine phosphate excretion from spot urine collection: development of a predictive equation","volume":"24","author":"Robinson-Cohen","year":"2014","journal-title":"Journal of Renal Nutrition"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub3-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/ckj\/sfu017","article-title":"Cardiovascular risk markers associated with arterial calcification in patients with chronic kidney disease stages 3 and 4","volume":"7","author":"Weber","year":"2014","journal-title":"Clinical Kidney Journal"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD006023.pub3-BIB0030|cit30","first-page":"iii156","article-title":"Ferric citrate reduces fibroblast growth factor 23 levels in patients with moderate chronic kidney disease [abstract]","volume":"29","author":"Block","year":"2014","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD006023.pub3-BIB0031|cit31","first-page":"iii151","article-title":"A double-blind placebo controlled randomized trial of ferric citrate coordination complex for the treatment of iron-deficiency anemia and reduction of serum phosphate in patients with non-dialysis dependent chronic kidney disease [abstract]","volume":"29","author":"Block","year":"2014","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub3-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"A23","DOI":"10.1053\/j.ajkd.2015.02.037","article-title":"Auryxia (ferric citrate) effectively reduces serum phosphate and fibroblast growth factor 23 (FGF23) levels in patients with stages 3-5 chronic kidney disease (CKD) [abstract]","volume":"65","author":"Block","year":"2015","journal-title":"American Journal of Kidney Diseases"},{"issue":"5","key":"10.1002\/14651858.CD006023.pub3-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1053\/j.ajkd.2014.10.014","article-title":"A 12-week, double-blind, placebo-controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD stages 3-5","volume":"65","author":"Block","year":"2015","journal-title":"American Journal of Kidney Diseases"},{"issue":"5","key":"10.1002\/14651858.CD006023.pub3-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"A118","DOI":"10.1053\/j.ajkd.2014.01.440","article-title":"ZerenexTM (ferric citrate) for the treatment of iron-deficiency anemia and reduction of serum phosphate in non-dialysis dependent CKD [abstract]","volume":"63","author":"Block","year":"2014","journal-title":"American Journal of Kidney Diseases"},{"issue":"11","key":"10.1002\/14651858.CD006023.pub3-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"e0188712","DOI":"10.1371\/journal.pone.0188712","article-title":"Safety and efficacy of ferric citrate in patients with nondialysis-dependent chronic kidney disease","volume":"12","author":"Chertow","year":"2017","journal-title":"PLoS ONE [Electronic Resource]"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub3-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"A35","DOI":"10.1053\/j.ajkd.2015.02.085","article-title":"Auryxia (ferric citrate), an oral iron-based phosphate binder significantly improves serum iron measures in patients with stage 3, 4 and 5 chronic kidney disease (CKD) [abstract]","volume":"65","author":"Fishbane","year":"2015","journal-title":"American Journal of Kidney Diseases"},{"key":"10.1002\/14651858.CD006023.pub3-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.bone.2016.07.009","article-title":"The pitfall of treating low bone turnover: effects on cortical porosity","volume":"91","author":"Araujo","year":"2016","journal-title":"Bone"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub3-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1111\/j.1523-1755.2005.00239.x","article-title":"Coronary calcification in hemodialysis patients: the contribution of traditional and uremia-related risk factors.[Erratum appears in Kidney Int. 2005 May;67(5):2085-7]","volume":"67","author":"Barreto","year":"2005","journal-title":"Kidney International"},{"issue":"6","key":"10.1002\/14651858.CD006023.pub3-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1053\/j.ajkd.2008.06.024","article-title":"Association of changes in bone remodeling and coronary calcification in hemodialysis patients: a prospective study.[Erratum appears in Am J Kidney Dis. 2009 Jan;53(1):181]","volume":"52","author":"Barreto","year":"2008","journal-title":"American Journal of Kidney Diseases"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub3-BIB0040|cit40","first-page":"c273","article-title":"Phosphate binder impact on bone remodeling and coronary calcification - results from the BRiC study","volume":"110","author":"Barreto","year":"2008","journal-title":"Nephron"},{"key":"10.1002\/14651858.CD006023.pub3-BIB0041|cit41","first-page":"738A","article-title":"Sevelamer and calcium acetate effects on bone histology in hemodialysis patients: one-year follow-up [abstract no: SA-PO831]","volume":"16","author":"Barreto","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD006023.pub3-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/sj.ki.5002769","article-title":"K\/DOQI-recommended intact PTH levels do not prevent low-turnover bone disease in hemodialysis patients","volume":"73","author":"Barreto","year":"2008","journal-title":"Kidney International"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub3-BIB0043|cit43","first-page":"c74","article-title":"Fibroblast growth factor 23 in hemodialysis patients: effects of phosphate binder, calcitriol and calcium concentration in the dialysate","volume":"117","author":"Cancela","year":"2011","journal-title":"Nephron"},{"issue":"Nov","key":"10.1002\/14651858.CD006023.pub3-BIB0044|cit44","first-page":"694A","article-title":"Bone and the relationship with inflammation and coronary calcification (BRIC) study [abstract no: SU-PO723]","volume":"14","author":"Canziani","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstracts","key":"10.1002\/14651858.CD006023.pub3-BIB0045|cit45","first-page":"532A","article-title":"Sevelamer (SEV), but not calcium acetate (CA), decreases serum fibroblast growth factor 23 (FGF23) in hemodialysis patients [abstract no: SA-PO863]","volume":"18","author":"Oliveira","year":"2007","journal-title":"Journal of the American Society of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub3-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1542-4758.2009.00369.x","article-title":"Effect of phosphate binders on oxidative stress and inflammation markers in hemodialysis patients","volume":"13","author":"Peres","year":"2009","journal-title":"Hemodialysis International"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub3-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1053\/ajkd.1998.v31.pm9469496","article-title":"Randomized crossover study comparing the phosphate-binding efficacy of calcium ketoglutarate versus calcium carbonate in patients on chronic hemodialysis","volume":"31","author":"Bro","year":"1998","journal-title":"American Journal of Kidney Diseases"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub3-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2215\/CJN.02810707","article-title":"Short-term treatment with sevelamer increases serum fetuin-a concentration and improves endothelial dysfunction in chronic kidney disease stage 4 patients","volume":"3","author":"Caglar","year":"2008","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub3-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1053\/j.ajkd.2011.11.007","article-title":"Comparison of calcium acetate and sevelamer on vascular function and fibroblast growth factor 23 in CKD patients: a randomized clinical trial","volume":"59","author":"Yilmaz","year":"2012","journal-title":"American Journal of Kidney Diseases"},{"issue":"9","key":"10.1002\/14651858.CD006023.pub3-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1093\/ndt\/gft203","article-title":"A comparison of calcium acetate\/magnesium carbonate and sevelamer-hydrochloride effects on fibroblast growth factor-23 and bone markers: post hoc evaluation from a controlled, randomized study","volume":"28","author":"Covic","year":"2013","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD006023.pub3-BIB0051|cit51","first-page":"iii40","article-title":"Serum calcification propensity of HD patients is therapeutically improved by a calcium acetate\/ magnesium carbonate containing phosphate binder [abstract]","volume":"29","author":"Pasch","year":"2014","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"11","key":"10.1002\/14651858.CD006023.pub3-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"3707","DOI":"10.1093\/ndt\/gfq292","article-title":"Evaluation of calcium acetate\/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability","volume":"25","author":"Francisco","year":"2010","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub3-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1159\/000186802","article-title":"Calcium acetate versus calcium carbonate as phosphate binders in hemodialysis patients","volume":"60","author":"Caravaca","year":"1992","journal-title":"Nephron"},{"issue":"8","key":"10.1002\/14651858.CD006023.pub3-BIB0054|cit54","first-page":"729","article-title":"Calcium acetate versus calcium carbonate as phosphate binders in haemodialysis patients [abstract]","volume":"5","author":"Caravaca","year":"1990","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Nov","key":"10.1002\/14651858.CD006023.pub3-BIB0055|cit55","first-page":"207A","article-title":"Treatment of hyperphosphatemia in dialysis patients: results of the calcium acetate renegel evaluation (CARE Study) [abstract no: F-PO664]","volume":"14","author":"Nolan","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD006023.pub3-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1111\/j.1523-1755.2004.00590.x","article-title":"Treatment of hyperphosphatemia in hemodialysis patients: the Calcium Acetate Renagel Evaluation (CARE Study)","volume":"65","author":"Qunibi","year":"2004","journal-title":"Kidney International"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub3-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.acra.2007.08.011","article-title":"The interscan variation of CT coronary artery calcification score: analysis of the Calcium Acetate Renagel Comparison (CARE)-2 study","volume":"15","author":"Budoff","year":"2008","journal-title":"Academic Radiology"},{"issue":"Oct Abstracts I","key":"10.1002\/14651858.CD006023.pub3-BIB0058|cit58","first-page":"866A","article-title":"Cardiovascular calcification (CVC) in hemodialysis (HD) patients: study design and preliminary mineral data of the calcium acetate sevelamer evaluation-2 (CARE-2) study [abstract no: PUB386]","volume":"16","author":"Qunibi","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 6","key":"10.1002\/14651858.CD006023.pub3-BIB0059|cit59","first-page":"vi148","article-title":"Progression of coronary artery calcification (CAC) in hemodialysis patients (HDP) despite excellent control of LDL cholesterol: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study [abstract no: FP386]","volume":"22","author":"Qunibi","year":"2007","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Abstracts","key":"10.1002\/14651858.CD006023.pub3-BIB0060|cit60","first-page":"286A","article-title":"Coronary artery calcification (CAC) in hemodialysis patients (HDP): preliminary results from the calcium acetate renagel evaluation-2 (CARE-2) study [abstract no: TH-PO845]","volume":"17","author":"Qunibi","year":"2006","journal-title":"Journal of the American Society of Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD006023.pub3-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1053\/j.ajkd.2008.02.298","article-title":"A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study","volume":"51","author":"Qunibi","year":"2008","journal-title":"American Journal of Kidney Diseases"},{"issue":"12","key":"10.1002\/14651858.CD006023.pub3-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"4081","DOI":"10.1093\/ndt\/gfn520","article-title":"The CARE-2 study results: setting the record straight","volume":"23","author":"Qunibi","year":"2008","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1002\/14651858.CD006023.pub3-BIB0063|cit63","unstructured":"Qunibi WY Moustafa M Kessler P Bortey E Muenz LR Budoff M Coronary artery calcification (CAC) progression in hemodialysis patients (HDP) treated with atorvastatin: the calcium acetate renagel evaluation-2 (CARE-2) study [abstract no: S-PO-0376] 4th World Congress of Nephrology.19th International Congress of the International Society of Nephrology (ISN); 2007 Apr 21-25; Rio de Janeiro, Brazil 2007 150"},{"issue":"Abstracts Issue","key":"10.1002\/14651858.CD006023.pub3-BIB0064|cit64","first-page":"10A","article-title":"Progression of aorta calcification (AoC) in hemodialysis patients (HDP) treated with calcium acetate (CaA) or sevelamer (SV) with comparable lipid control: the calcium acetate renegal evaluation-2 (CARE-2) study [abstract no: TH-FC043]","volume":"19","author":"Qunibi","year":"2008","journal-title":"Journal of the American Society of Nephrology"},{"issue":"8","key":"10.1002\/14651858.CD006023.pub3-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/j.1440-1797.2011.01509.x","article-title":"Efficacy and safety of SBR759, a novel calcium-free, iron(III)-based phosphate binder, in Asian patients undergoing hemodialysis: a 12-week, randomized, open-label, dose-titration study versus sevelamer hydrochloride","volume":"16","author":"Chen","year":"2011","journal-title":"Nephrology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD006023.pub3-BIB0066|cit66","first-page":"51","article-title":"SBR759, a novel phosphate binder, effectively controls hyperphosphatemia in Asian patients on hemodialysis versus sevelamer [abstract no: FP08-08]","volume":"15","author":"Chen","year":"2010","journal-title":"Nephrology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD006023.pub3-BIB0067|cit67","first-page":"iii238","article-title":"SBR759, a novel phosphate binder, is superior to sevelamer HCL in controlling hyperphosphatemia in Asian patients on hemodialysis [abstract no: Sa582]","volume":"3","author":"Chen","year":"2010","journal-title":"NDT Plus"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub3-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/ndt\/gft232","article-title":"Sevelamer carbonate lowers serum phosphorus effectively in haemodialysis patients: a randomized, double-blind, placebo-controlled, dose-titration study","volume":"29","author":"Chen","year":"2014","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Abstracts","key":"10.1002\/14651858.CD006023.pub3-BIB0069|cit69","first-page":"924A","article-title":"The effect of oral niacinamide on serum phosphorus levels in hemodialysis patients [abstract no: PUB430]","volume":"18","author":"Cheng","year":"2007","journal-title":"Journal of the American Society of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub3-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.2215\/CJN.04211007","article-title":"A randomized, double-blind, placebo-controlled trial of niacinamide for reduction of phosphorus in hemodialysis patients","volume":"3","author":"Cheng","year":"2008","journal-title":"Clinical Journal of The American Society of Nephrology: CJASN"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub3-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1755-6686.2013.12009.x","article-title":"Comparison of sevelamer and calcium carbonate on endothelial function and inflammation in patients on peritoneal dialysis","volume":"39","author":"Chennasamudram","year":"2013","journal-title":"Journal of Renal Care"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub3-BIB0072|cit72","first-page":"18","article-title":"A randomized trial of sevelamer hydrochloride (RenaGel) with and without supplemental calcium. Strategies for the control of hyperphosphatemia and hyperparathyroidism in hemodialysis patients","volume":"51","author":"Chertow","year":"1999","journal-title":"Clinical Nephrology"},{"issue":"8","key":"10.1002\/14651858.CD006023.pub3-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1093\/ndt\/gfh894","article-title":"Two year comparison of sevelamer and calcium carbonate effects on cardiovascular calcification and bone density","volume":"20","author":"Asmus","year":"2005","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006023.pub3-BIB0074|cit74","first-page":"32","article-title":"Sevelamer is more effective than calcium in the management of mineral metabolism and arterial calcification [abstract no: O106]","volume":"17","author":"Bommer","year":"2002","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"6","key":"10.1002\/14651858.CD006023.pub3-BIB0075|cit75","first-page":"A122","article-title":"Lipid lowering effect of renagel, a novel phosphate binder [abstract]","volume":"16","author":"Bommer","year":"2001","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub3-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"104","DOI":"10.5414\/CNP62104","article-title":"Long-term comparison of a calcium-free phosphate binder and calcium carbonate--phosphorus metabolism and cardiovascular calcification","volume":"62","author":"Braun","year":"2004","journal-title":"Clinical Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub3-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1046\/j.1523-1755.2002.00434.x","article-title":"Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients","volume":"62","author":"Chertow","year":"2002","journal-title":"Kidney International"},{"issue":"September, Prog","key":"10.1002\/14651858.CD006023.pub3-BIB0078|cit78","first-page":"433a","article-title":"The \"tip of the iceberg\" matters: exposure to high normal serum calcium concentration leads to accelerated coronary artery and aortic calcification in hemodialysis patients treated with calcium-based phosphate binders [abstract]","volume":"13","author":"Chertow","year":"2002","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD006023.pub3-BIB0079|cit79","first-page":"195","article-title":"Sevelamer is more effective at controlling disorders of mineral metabolism than calcium-based phosphate binders in hemodialysis patients [abstract]","volume":"12","author":"Chertow","year":"2001","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Sept, Program &","key":"10.1002\/14651858.CD006023.pub3-BIB0080|cit80","first-page":"386a","article-title":"In hemodialysis patients, sevelamer (renagel) attenuates coronary artery and aortic calcification and reduces LDL-C, APO-B, and HS-CRP compared with calcium acetate (PHOSLO) [abstract no: SA-PO603]","volume":"13","author":"Chertow","year":"2002","journal-title":"Journal of the American Society of Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD006023.pub3-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1093\/ndt\/gfh125","article-title":"Determinants of progressive vascular calcification in haemodialysis patients","volume":"19","author":"Chertow","year":"2004","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"5","key":"10.1002\/14651858.CD006023.pub3-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1159\/000072822","article-title":"The effects of sevelamer and calcium acetate on proxies of atherosclerotic and arteriosclerotic vascular disease in hemodialysis patients","volume":"23","author":"Chertow","year":"2003","journal-title":"American Journal of Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD006023.pub3-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.ahj.2004.07.023","article-title":"Potential antiatherogenic and anti-inflammatory properties of sevelamer in maintenance hemodialysis patients","volume":"149","author":"Ferramosca","year":"2005","journal-title":"American Heart Journal"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub3-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/art.20781","article-title":"Effects of sevelamer and calcium-based phosphate binders on uric acid concentrations in patients undergoing hemodialysis: a randomized clinical trial","volume":"52","author":"Garg","year":"2005","journal-title":"Arthritis & Rheumatism"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD006023.pub3-BIB0085|cit85","first-page":"681","article-title":"Thoracic vertebral bone density increases with renagel and decreases with calcium-based phosphate binder therapy - a two year study [abstract no: W423]","volume":"18","author":"James","year":"2003","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub3-BIB0086|cit86","first-page":"134","article-title":"Valvular calcification in hemodialysis patients randomized to calcium-based phosphorus binders or sevelamer","volume":"13","author":"Raggi","year":"2004","journal-title":"Journal of Heart Valve Disease"},{"key":"10.1002\/14651858.CD006023.pub3-BIB0087|cit87","unstructured":"Raggi P Burke S Chasen-Taber S Chertow G Holzer H Bommer J Sevelamer preserves trabecular bone mineral density [abstract] 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal 2004 103 4"},{"issue":"Nov","key":"10.1002\/14651858.CD006023.pub3-BIB0088|cit88","first-page":"502A","article-title":"Sevelamer preserves and calcium reduces trabecular bone mineral density [abstract no: SA-PO924]","volume":"14","author":"Raggi","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD006023.pub3-BIB0089|cit89","first-page":"239A","article-title":"Sevelamer attenuates the progression of coronary and aortic calcification compared with calcium-based phosphate binders [abstract]","volume":"12","author":"Raggi","year":"2001","journal-title":"Journal of the American Society of Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD006023.pub3-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1359\/JBMR.041221","article-title":"Decrease in thoracic vertebral bone attenuation with calcium-based phosphate binders in hemodialysis","volume":"20","author":"Raggi","year":"2005","journal-title":"Journal of Bone & Mineral Research"},{"issue":"5","key":"10.1002\/14651858.CD006023.pub3-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1681\/ASN.2012070719","article-title":"Cardiovascular effects of sevelamer in stage 3 CKD","volume":"24","author":"Chue","year":"2013","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub3-BIB0092|cit92","first-page":"30","article-title":"Evaluating the effects of sevelamer carbonate on cardiovascular structure and function in chronic renal impairment in Birmingham: the CRIB-PHOS randomised controlled trial","volume":"12","author":"Chue","year":"2011","journal-title":"Trials [Electronic Resource]"},{"key":"10.1002\/14651858.CD006023.pub3-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1046\/j.1523-1755.63.s85.18.x","article-title":"A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients","volume":"85","author":"D'Haese","year":"2003","journal-title":"Kidney International - Supplement"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006023.pub3-BIB0094|cit94","first-page":"A28","article-title":"Multi-centre study on the effects of lanthanum carbonate (FosrenolTM) and calcium carbonate on renal bone disease in dialysis patients [abstract no: PS1-15]","volume":"8","author":"D'Haese","year":"2003","journal-title":"Nephrology"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD006023.pub3-BIB0095|cit95","first-page":"682","article-title":"Comparative effects of lanthanum carbonate (fosrenol) and calcium carbonate on renal bone disease in dialysis patients: results from a large, long-term clinical trial [abstract]","volume":"18","author":"Broe","year":"2003","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub3-BIB0097|cit96","first-page":"A23","article-title":"The effects of lanthanum carbonate and calcium carbonate on bone in patients with chronic kidney disease [abstract no: 33]","volume":"43","author":"Freemont","year":"2004","journal-title":"American Journal of Kidney Diseases"},{"key":"10.1002\/14651858.CD006023.pub3-BIB0096|cit97","unstructured":"Freemont A Jones C The effects of the phosphate binders lanthanum carbonate and calcium carbonate on bone: a comparative study in patients with chronic kidney disease [abstract no:SP270] 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal 2004 106"},{"issue":"6","key":"10.1002\/14651858.CD006023.pub3-BIB0098|cit98","first-page":"428","article-title":"The effects of lanthanum carbonate and calcium carbonate on bone abnormalities in patients with end-stage renal disease","volume":"64","author":"Freemont","year":"2005","journal-title":"Clinical Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub3-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"138","DOI":"10.5414\/CNP63138","article-title":"Utilization of bone histomorphometry in renal osteodystrophy: demonstration of a new approach using data from a prospective study of lanthanum carbonate","volume":"63","author":"Freemont","year":"2005","journal-title":"Clinical Nephrology"},{"issue":"Nov","key":"10.1002\/14651858.CD006023.pub3-BIB0100|cit100","first-page":"764A","article-title":"One-year, randomized, open-label study comparing the safety and efficacy of lanthanum carbonate (Fosrenol\u00ae) and calcium carbonate in dialysis patients [abstract no: SU-PO1041]","volume":"14","author":"Torres","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub3-BIB0101|cit101","first-page":"146","article-title":"Lanthanum carbonate, a novel phosphate binder, has similar efficacy and tolerability to calcium carbonate over one year of treatment [abstract]","volume":"31","author":"Webster","year":"2004","journal-title":"Nephrology Nursing Journal"},{"key":"10.1002\/14651858.CD006023.pub3-BIB0103|cit102","unstructured":"Wilson R Spica Consultants Ltd Personal communication 2005"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD006023.pub3-BIB0102|cit103","first-page":"ii496","article-title":"Lower serum phosphorus can be attained by increasing the dose of lanthanum carbonate [abstract]","volume":"27","author":"Wilson","year":"2012","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Abstracts","key":"10.1002\/14651858.CD006023.pub3-BIB0104|cit104","first-page":"287A","article-title":"DCOR Study: assessing impact of sevelamer vs calcium binders on hospitalization and morbidity in hemodialysis patients using CMS data [abstract no: TH-PO846]","volume":"17","author":"Peter","year":"2006","journal-title":"Journal of the American Society of Nephrology"},{"issue":"12","key":"10.1002\/14651858.CD006023.pub3-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.2215\/CJN.04100609","article-title":"Economic evaluation of sevelamer versus calcium-based phosphate binders in hemodialysis patients: a secondary analysis using centers for Medicare & Medicaid services data","volume":"4","author":"Peter","year":"2009","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub3-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1053\/j.ajkd.2007.12.002","article-title":"A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data","volume":"51","author":"Peter","year":"2008","journal-title":"American Journal of Kidney Diseases"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub3-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1111\/j.1542-4758.2008.00312.x","article-title":"Linking Centers for Medicare & Medicaid Services data with prospective DCOR trial data: methods and data comparison results","volume":"12","author":"Peter","year":"2008","journal-title":"Hemodialysis International"},{"issue":"Abstracts","key":"10.1002\/14651858.CD006023.pub3-BIB0108|cit108","first-page":"287A","article-title":"DCOR Study: assessing economic impact of sevelamer vs calcium binders on hospitalization and morbidity in hemodialysis patients using CMS data [abstract no: TH-PO847]","volume":"17","author":"St.Peter","year":"2006","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD006023.pub3-BIB0109|cit109","first-page":"iv145","article-title":"A prospective, randomized trial assessing the impact on outcomes of sevelamer in dialysis patients - the DCOR trial [abstract no: SP392]","volume":"21","author":"Suki","year":"2006","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1002\/14651858.CD006023.pub3-BIB0110|cit110","first-page":"281A","article-title":"The DCOR trial - a prospective, randomized trial assessing the impact on outcomes of sevelamer in dialysis patients [abstract no: TH-PO745]","volume":"16","author":"Suki","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"issue":"9","key":"10.1002\/14651858.CD006023.pub3-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1038\/sj.ki.5002466","article-title":"Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients","volume":"72","author":"Suki","year":"2007","journal-title":"Kidney International"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub3-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1053\/j.jrn.2007.10.019","article-title":"Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients: results of a randomized clinical trial","volume":"18","author":"Suki","year":"2008","journal-title":"Journal of Renal Nutrition"},{"key":"10.1002\/14651858.CD006023.pub3-BIB0113|cit113","unstructured":"Delmez JA Kelber J Norwood KY Giles KS Slatopolsky E The clinical evaluation of magnesium carbonate (MgCo3) as a phosphorous (P) binder in the suppression of secondary hyperparathyroidism [abstract] ISN XIII International Congress of Nephrology; 1995 Jul 2-6; Madrid, Spain 1995 416"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub3-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/ki.1996.22","article-title":"Magnesium carbonate as a phosphorus binder: a prospective, controlled, crossover study","volume":"49","author":"Delmez","year":"1996","journal-title":"Kidney International"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub3-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"A36","DOI":"10.1053\/j.ajkd.2007.02.052","article-title":"A randomized, double-blind cross-over design study of sevelamer hydrochloride (SH, Renegel\u00ae) and sevelamer carbonate (SC) in chronic kidney disease patients on hemodialysis [abstract no: 48]","volume":"49","author":"Delmez","year":"2007","journal-title":"American Journal of Kidney Diseases"},{"issue":"Suppl 6","key":"10.1002\/14651858.CD006023.pub3-BIB0116|cit116","first-page":"vi361","article-title":"Results of a randomized, double-blind, cross-over design study of sevelamer hydrochloride (Renagel\u00ae) and sevelamer carbonate in chronic kidney disease patients on hemodialysis [abstract no: SaP377]","volume":"22","author":"Delmez","year":"2007","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"6","key":"10.1002\/14651858.CD006023.pub3-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"386","DOI":"10.5414\/CNP68386","article-title":"A randomized, double-blind, crossover design study of sevelamer hydrochloride and sevelamer carbonate in patients on hemodialysis","volume":"68","author":"Delmez","year":"2007","journal-title":"Clinical Nephrology"},{"key":"10.1002\/14651858.CD006023.pub3-BIB0118|cit118","first-page":"S108","article-title":"Sevelamer worsens metabolic acidosis in hemodialysis patients","volume":"19 Suppl 9","author":"Santo","year":"2006","journal-title":"Journal of Nephrology"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD006023.pub3-BIB0119|cit119","first-page":"680","article-title":"Effective reduction of serum phosphate by a calcium and magnesium containing phosphate binder without induction of hypermagnesemia [abstract no: W422]","volume":"18","author":"Deuber","year":"2003","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"8","key":"10.1002\/14651858.CD006023.pub3-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"403","DOI":"10.5414\/NHP33403","article-title":"Combined use of calcium acetate and magnesium carbonate as phosphate binder","volume":"33","author":"Deuber","year":"2004","journal-title":"Nieren und Hochdruckkrankheiten"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub3-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1093\/ndt\/gfn488","article-title":"Efficacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis","volume":"24","author":"Evenepoel","year":"2009","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD006023.pub3-BIB0122|cit122","first-page":"iv496","article-title":"Effects of sevelamer hydrochloride (Renagel\u00ae) and calcium acetate on controlling serum phosphorus in peritoneal dialysis patients [abstract no: MP580]","volume":"21","author":"Evenepoel","year":"2006","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Abstracts","key":"10.1002\/14651858.CD006023.pub3-BIB0123|cit123","first-page":"272A","article-title":"Comparative effects of sevelamer hydrochloride (Renagel\u00ae) and calcium acetate on markers of mineral metabolism in peritoneal dialysis patients [abstract no: TH-PO778]","volume":"17","author":"Evenepoel","year":"2006","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub3-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3747\/pdi.2013.00129","article-title":"MgCaCO3 versus CaCO3 in peritoneal dialysis patients--a cross-over pilot trial","volume":"35","author":"Evsanaa","year":"2015","journal-title":"Peritoneal Dialysis International"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub3-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1681\/ASN.2006101089","article-title":"Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients","volume":"19","author":"Ferreira","year":"2008","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD006023.pub3-BIB0126|cit126","unstructured":"Fishbane S Delmez J Suki W Hariachar S Moe S Heaton J Sevelamer carbonate powder dosed once per day and sevelamer hydrochloride tablets dosed three times per day: a randomized, parallel, open-label study in chronic kidney disease patients on hemodialysis [abstract no: M621] World Congress of Nephrology; 2009 May 22-26; Milan, Italy 2009"},{"issue":"Abstracts Issue","key":"10.1002\/14651858.CD006023.pub3-BIB0127|cit127","first-page":"936A","article-title":"A randomized, parallel, open-label study to compare once per day sevelamer carbonate powder dosing with three times per day sevelamer hydrochloride tablet dosing in chronic kidney disease patients on hemodialysis [abstract no: PUB556]","volume":"19","author":"Fishbane","year":"2008","journal-title":"Journal of the American Society of Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub3-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1053\/j.ajkd.2009.10.051","article-title":"A randomized, parallel, open-label study to compare once-daily sevelamer carbonate powder dosing with thrice-daily sevelamer hydrochloride tablet dosing in CKD patients on hemodialysis","volume":"55","author":"Fishbane","year":"2010","journal-title":"American Journal of Kidney Diseases"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD006023.pub3-BIB0129|cit129","first-page":"iii153","article-title":"Comparison of safety profiles of PA21 and sevelamer carbonate in a post hoc analysis of a phase 3 study [abstract]","volume":"29","author":"Covic","year":"2014","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD006023.pub3-BIB0130|cit130","first-page":"iii152","article-title":"Efficacy and safety of PA21 and sevelamer carbonate in haemodialysis patients with or without diabetes: a post hoc analysis of a phase 3 study [abstract]","volume":"29","author":"Covic","year":"2014","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"8","key":"10.1002\/14651858.CD006023.pub3-BIB0131|cit131","first-page":"1330","article-title":"Iron-related parameters in dialysis patients treated with sucroferric oxyhydroxide","volume":"32","author":"Covic","year":"2017","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD006023.pub3-BIB0132|cit132","first-page":"iii157","article-title":"PA21 does not interact with oral vitamin D receptor agonists: a post hoc analysis of a phase 3 study [abstract]","volume":"29","author":"Floege","year":"2014","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006023.pub3-BIB0133|cit133","first-page":"i155","article-title":"Regional analysis of baseline characteristics in a phase 3 study of PA21, a novel iron-based phosphate binder [abstract]","volume":"28","author":"Floege","year":"2013","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"11","key":"10.1002\/14651858.CD006023.pub3-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1093\/ndt\/gfw460","article-title":"One-year efficacy and safety of the iron-based phosphate binder sucroferric oxyhydroxide in patients on peritoneal dialysis","volume":"32","author":"Floege","year":"2017","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"6","key":"10.1002\/14651858.CD006023.pub3-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1093\/ndt\/gfv006","article-title":"Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients","volume":"30","author":"Floege","year":"2015","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub3-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/ki.2014.58","article-title":"A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients","volume":"86","author":"Floege","year":"2014","journal-title":"Kidney International"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD006023.pub3-BIB0137|cit137","first-page":"iii152","article-title":"Post hoc analysis of safety profiles by patient age in a phase 3 study of PA21 and sevelamer carbonate [abstract]","volume":"29","author":"Floege","year":"2014","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006023.pub3-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"i461","DOI":"10.1093\/ndt\/gfw190.22","article-title":"Sucroferric oxyhydroxide does not impact the iPTH-lowering effects of oral vdras or cinacalcet: a post hoc analysis of a phase 3 study [abstract]","volume":"31","author":"Floege","year":"2016","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006023.pub3-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"i466","DOI":"10.1093\/ndt\/gfw190.38","article-title":"Characteristics of responders and non-responders to treatment with sucroferric oxyhydroxide: a post hoc analysis of a phase 3 study [abstract]","volume":"31","author":"Floege","year":"2016","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006023.pub3-BIB0140|cit140","first-page":"i155","article-title":"PA21, a novel iron-based phosphate binder, showed no interaction with fat-soluble vitamins in a phase 3 study [abstract]","volume":"28","author":"Ketteler","year":"2013","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub3-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"A81","DOI":"10.1053\/j.ajkd.2013.02.266","article-title":"PA21 - a novel iron-based phosphate binder with a low pill burden: tolerance in dialysis patients [abstract]","volume":"61","author":"Rastogi","year":"2013","journal-title":"American Journal of Kidney Diseases"},{"issue":"5","key":"10.1002\/14651858.CD006023.pub3-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"A94","DOI":"10.1053\/j.ajkd.2014.01.318","article-title":"No clinically relevant changes in vitamin D concentrations with PA21, a novel iron-based phosphate binder, over 52 weeks [abstract]","volume":"63","author":"Rastogi","year":"2014","journal-title":"American Journal of Kidney Diseases"},{"issue":"5","key":"10.1002\/14651858.CD006023.pub3-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"A105","DOI":"10.1053\/j.ajkd.2014.01.364","article-title":"Concomitant intravenous iron use drives changes in iron indices in a phase 3 study of PA21 [abstract]","volume":"63","author":"Sprague","year":"2014","journal-title":"American Journal of Kidney Diseases"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub3-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"A80","DOI":"10.1053\/j.ajkd.2015.02.264","article-title":"Post HOC analysis of antianemic agent use over 1 year in a phase 3 study of sucroferric oxyhydroxide [abstract]","volume":"65","author":"Sprague","year":"2015","journal-title":"American Journal of Kidney Diseases"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub3-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1159\/000447600","article-title":"Pharmacodynamic effects of sucroferric oxyhydroxide and sevelamer carbonate on vitamin D receptor agonist bioactivity in dialysis patients","volume":"44","author":"Sprague","year":"2016","journal-title":"American Journal of Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD006023.pub3-BIB0146|cit146","first-page":"A104","article-title":"1-year efficacy and safety of sucroferric oxyhydroxide in a sub-population of African American dialysis patients [abstract]","volume":"67","author":"Sprague","year":"2016","journal-title":"American Journal of Kidney Diseases"},{"issue":"5","key":"10.1002\/14651858.CD006023.pub3-BIB0147|cit147","first-page":"A104","article-title":"FGF-23 and CKD-MBD indices after 1 year of treatment with sucroferric oxyhydroxide in African American dialysis patients [abstract]","volume":"67","author":"Sprague","year":"2016","journal-title":"American Journal of Kidney Diseases"},{"issue":"1-3","key":"10.1002\/14651858.CD006023.pub3-BIB0148|cit148","first-page":"212","article-title":"Evaluating the management of hyperphosphatemia with PA21 in dialysis patients-rationale and design of an open-label, randomised, active-controlled phase 3 study [abstract]","volume":"33","author":"Tumlin","year":"2012","journal-title":"Blood Purification"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub3-BIB0149|cit149","first-page":"296","article-title":"Calcium acetate. A good alternative to calcium carbonate for treating hyperphosphoremia in chronic hemodialysis patients with high risk of hypercalcemia","volume":"18","author":"Foraster","year":"1998","journal-title":"Nefrologia"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD006023.pub3-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"iii645","DOI":"10.1093\/ndt\/gfx177.MP586","article-title":"Effect of lanthanum carbonate on cardiac abnormalities in patients new to hemodialysis [abstract]","volume":"32","author":"Fujii","year":"2017","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006023.pub3-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"i252","DOI":"10.1093\/ndt\/gfw172.17","article-title":"Effect of lanthanum carbonate on coronary artery calcification during the early period after the initiation of haemodialysis [abstract]","volume":"31","author":"Fujii","year":"2016","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD006023.pub3-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"iii244","DOI":"10.1093\/ndt\/gfx147.SP387","article-title":"Comparison of the suppressive effects on fibroblast growth factor 23 between ferric citrate and lanthanum carbonate [abstract]","volume":"32","author":"Fujimori","year":"2017","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1002\/14651858.CD006023.pub3-BIB0153|cit153","first-page":"746A","article-title":"Comparison of sevelamer HCL and calcium carbonate in the treatment of hyperphosphatemia in dialysis patients: a randomized clinical trial - Calcium Carbonate Sevelamer Evaluation (CaCSE) study [abstract]","volume":"16","author":"Gallieni","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD006023.pub3-BIB0154|cit154","unstructured":"Greenberg S Shapiro W Poruch JG Calcium acetate (aa) vs calcium carbonate (caco) as a phosphorus (p) binder (b) in CAPD patients (pts) [abstract] ISN XIII International Congress of Nephrology; 1995 Jul 2-6; Madrid, Spain 1995 472"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub3-BIB0155|cit155","first-page":"492","article-title":"Calcium acetate (caa) vs calcium carbonate (caco) as a phosphorus (p) binder (b) in CAPD patients (pts) [abstract]","volume":"5","author":"Greenberg","year":"1994","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD006023.pub3-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1046\/j.1523-1755.63.s85.17.x","article-title":"Treatment of hyperphosphatemia with sevelamer hydrochloride in hemodialysis patients: a comparison with calcium acetate","volume":"85","author":"Hervas","year":"2003","journal-title":"Kidney International - Supplement"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub3-BIB0157|cit157","first-page":"141","article-title":"Efficacy and safety of lanthanum carbonate, the novel phosphate binder, in Chinese patients with chronic kidney disease [abstract]","volume":"31","author":"Gill","year":"2004","journal-title":"Nephrology Nursing Journal"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD006023.pub3-BIB0158|cit158","first-page":"v92","article-title":"Analysis of haematology data from over 2000 dialysis patients participating in clinical trials on the new phosphate binder, lanthanum carbonate [abstract no: SP219]","volume":"20","author":"Hutchison","year":"2005","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl","key":"10.1002\/14651858.CD006023.pub3-BIB0159|cit159","first-page":"A297","article-title":"No adverse effects of haematological parameters during lanthanum carbonate treatment in over 2000 patients [abstract no: W-PO40068]","volume":"10","author":"Hutchison","year":"2005","journal-title":"Nephrology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006023.pub3-BIB0160|cit160","first-page":"A297","article-title":"Long-term safety, efficacy, and tolerability of lanthanum carbonate: results from a 3.5-year study [abstract no: W-PO40065]","volume":"10","author":"Hutchison","year":"2005","journal-title":"Nephrology"},{"issue":"Nov","key":"10.1002\/14651858.CD006023.pub3-BIB0162|cit161","first-page":"205A","article-title":"Lanthanum carbonate versus calcium carbonate: effect on parathyroid hormone (PTH) levels [abstract no: F-PO656]","volume":"14","author":"Hutchison","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Nov","key":"10.1002\/14651858.CD006023.pub3-BIB0163|cit162","first-page":"764A","article-title":"Maintained safety, tolerability and efficacy of lanthanum carbonate (Fosrenal\u00ae) during long-term therapy in hemodialysis patients. [abstract no: SU-PO1039]","volume":"14","author":"Hutchison","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD006023.pub3-BIB0164|cit163","unstructured":"Hutchison A Webster I Safety and efficacy data for lanthanum carbonate: a summary from three studies [abstract] 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal 2004 107"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD006023.pub3-BIB0161|cit164","first-page":"684","article-title":"Safety and tolerability of lanthanum carbonate in haemodialysis patients: a 12-month study [abstract no: W431]","volume":"18","author":"Hutchison","year":"2003","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl","key":"10.1002\/14651858.CD006023.pub3-BIB0165|cit165","first-page":"A298","article-title":"No evidence of hepatoxicity with lanthanum carbonate - clinical trial data from 2000 dialysis patients [abstract no: W-PO40069]","volume":"10","author":"Hutchison","year":"2005","journal-title":"Nephrology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006023.pub3-BIB0169|cit166","first-page":"A29","article-title":"Lanthanum carbonate (FosrenolTM), a novel, nonaluminum, noncalcium phosphate binder, is effective and well tolerated in hyperphosphatemia [abstract no: PS1-22]","volume":"8","author":"Hutchison","year":"2003","journal-title":"Nephrology"},{"key":"10.1002\/14651858.CD006023.pub3-BIB0166|cit167","unstructured":"Hutchison AJ Gill M A demographic analysis of lanthanum carbonate phase II and III studies [abstract no: 271] 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal 2004 106 7"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub3-BIB0167|cit168","first-page":"c8","article-title":"Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: A 6-month, randomized, comparative trial versus calcium carbonate","volume":"100","author":"Hutchison","year":"2005","journal-title":"Nephron"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub3-BIB0168|cit169","first-page":"c61","article-title":"Long-term efficacy and tolerability of lanthanum carbonate: results from a 3-year study","volume":"102","author":"Hutchison","year":"2006","journal-title":"Nephron"},{"issue":"September, Prog","key":"10.1002\/14651858.CD006023.pub3-BIB0170|cit170","first-page":"385A","article-title":"The novel, non-aluminium, non-calcium phosphate binder, fosrenol, is an effective treatment for hyperphosphataemia and has a good safety profile [abstract no: SA-PO599]","volume":"13","author":"Hutchison","year":"2002","journal-title":"Journal of the American Society of Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub3-BIB0171|cit171","first-page":"149","article-title":"Lanthanum carbonate, a novel, non-aluminum, non-calcium phosphate binder, is effective and well tolerated in hyperphosphatemia [abstract]","volume":"30","author":"Speake","year":"2003","journal-title":"Nephrology Nursing Journal"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub3-BIB0172|cit172","first-page":"143","article-title":"Long-term safety, tolerability, and efficacy of lanthanum carbonate therapy [abstract]","volume":"31","author":"Speake","year":"2004","journal-title":"Nephrology Nursing Journal"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub3-BIB0174|cit173","first-page":"146","article-title":"Lanthanum carbonate, a novel phosphate binder, has similar efficacy and tolerability to calcium carbonate over one year of treatment [abstract]","volume":"31","author":"Webster","year":"2004","journal-title":"Nephrology Nursing Journal"},{"key":"10.1002\/14651858.CD006023.pub3-BIB0173|cit174","unstructured":"Webster I Gill M Lanthanum carbonate, a new phosphate binder, is well tolerated over a 3 year period in dialysis patients [abstract no: SP267] 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal 2004 105"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD006023.pub3-BIB0175|cit175","first-page":"ii127","article-title":"Effect of phosphate binder therapy on mortality in pre-dialysis patients [abstract]","volume":"27","author":"Iorio","year":"2012","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub3-BIB0176|cit176","first-page":"487","article-title":"Mortality in kidney disease patients treated with phosphate binders: a randomized study.[Erratum appears in Clin J Am Soc Nephrol. 2012 Aug;7(8):1370-1]","volume":"7","author":"Iorio","year":"2012","journal-title":"Clinical Journal of The American Society of Nephrology: CJASN"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub3-BIB0177|cit177","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1159\/000365746","article-title":"Sevelamer is cost-saving vs. calcium carbonate in non-dialysis-dependent CKD patients in Italy: a patient-level cost-effectiveness analysis of the INDEPENDENT study","volume":"37","author":"Ruggeri","year":"2014","journal-title":"Blood Purification"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub3-BIB0178|cit178","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s40620-014-0071-2","article-title":"Effects of phosphorus-restricted diet and phosphate-binding therapy on outcomes in patients with chronic kidney disease","volume":"28","author":"Russo","year":"2015","journal-title":"Journal of Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD006023.pub3-BIB0179|cit179","doi-asserted-by":"crossref","first-page":"744","DOI":"10.3111\/13696998.2013.792267","article-title":"Economic evaluation of sevelamer for the treatment of hyperphosphatemia in chronic kidney disease patients not on dialysis in the United Kingdom","volume":"16","author":"Thompson","year":"2013","journal-title":"Journal of Medical Economics"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub3-BIB0180|cit180","first-page":"49","article-title":"Cost-effectiveness of sevelamer versus calcium carbonate in non-dialysis dependent chronic kidney disease patients in Spain","volume":"13","author":"Pino","year":"2016","journal-title":"Pharmacoeconomics - Spanish Research Articles"},{"issue":"9","key":"10.1002\/14651858.CD006023.pub3-BIB0181|cit181","doi-asserted-by":"crossref","first-page":"113","DOI":"10.5414\/CN108827","article-title":"Cinacalcet but not vitamin D use modulates the survival benefit associated with sevelamer in the INDEPENDENT study","volume":"86","author":"Bellasi","year":"2016","journal-title":"Clinical Nephrology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD006023.pub3-BIB0182|cit182","doi-asserted-by":"crossref","first-page":"iii588","DOI":"10.1093\/ndt\/gfv199.01","article-title":"Cinacalcet but not vitamin D use modulates the survival benefit associated with sevelamer in the INDEPENDENT study [abstract]","volume":"30","author":"Bellasi","year":"2015","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub3-BIB0184|cit183","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1053\/j.ajkd.2013.09.005","article-title":"In reply to 'The change history of the INDEPENDENT Study in the ClinicalTrials.gov database'","volume":"63","author":"Iorio","year":"2014","journal-title":"American Journal of Kidney Diseases"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub3-BIB0183|cit184","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1053\/j.ajkd.2013.03.023","article-title":"Sevelamer versus calcium carbonate in incident hemodialysis patients: results of an open-label 24-month randomized clinical trial","volume":"62","author":"Iorio","year":"2013","journal-title":"American Journal of Kidney Diseases"},{"issue":"6","key":"10.1002\/14651858.CD006023.pub3-BIB0185|cit185","first-page":"694","article-title":"Vascular calcification and QT interval in incident hemodialysis patients.[Erratum appears in J Nephrol. 2010 Jan-Feb;23(1):124], [Erratum appears in J Nephrol. 2013 Mar-Apr;26(2):419]","volume":"22","author":"Iorio","year":"2009","journal-title":"Journal of Nephrology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD006023.pub3-BIB0186|cit186","first-page":"ii54","article-title":"Sevelamer attenuates CV mortality in incident hemodialysis patients: open label, randomized clinical trial of efficacy and safety (INDEPENDENT study) [abstract]","volume":"27","author":"Molony","year":"2012","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub3-BIB0187|cit187","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1053\/j.ajkd.2013.08.022","article-title":"The change history of the INDEPENDENT Study in the ClinicalTrials.gov database","volume":"63","author":"Obi","year":"2014","journal-title":"American Journal of Kidney Diseases"},{"issue":"6","key":"10.1002\/14651858.CD006023.pub3-BIB0188|cit188","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s40620-014-0128-2","article-title":"Erratum to: Sevelamer is cost effective versus calcium carbonate for the first-line treatment of hyperphosphatemia in new patients to hemodialysis: a patient-level economic evaluation of the INDEPENDENT-HD study.[Erratum for J Nephrol. 2015 Oct;28(5):593-602; PMID: 25027030]","volume":"27","author":"Ruggeri","year":"2014","journal-title":"Journal of Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD006023.pub3-BIB0189|cit189","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s40620-014-0122-8","article-title":"Sevelamer is cost effective versus calcium carbonate for the first-line treatment of hyperphosphatemia in new patients to hemodialysis: a patient-level economic evaluation of the INDEPENDENT-HD study.[Erratum appears in J Nephrol. 2014 Dec;27(6):717; PMID: 25098354]","volume":"28","author":"Ruggeri","year":"2015","journal-title":"Journal of Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD006023.pub3-BIB0190|cit190","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.2215\/CJN.09250912","article-title":"Effects of dietary phosphate restriction and phosphate binders on FGF23 Levels in CKD","volume":"8","author":"Isakova","year":"2013","journal-title":"Clinical Journal of The American Society of Nephrology: CJASN"},{"key":"10.1002\/14651858.CD006023.pub3-BIB0191|cit191","first-page":"45A","article-title":"Effects of dietary phosphate restriction and lanthanum carbonate on fibroblast growth factor 23 in chronic kidney disease [abstract no: FR-OR068]","volume":"23","author":"Isakova","year":"2012","journal-title":"Journal of the American Society of Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub3-BIB0192|cit192","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/j.1744-9987.2008.00557.x","article-title":"Comparison of sevelamer hydrochloride with colestimide, administered alone or in combination with calcium carbonate, in patients on hemodialysis","volume":"12","author":"Itoh","year":"2008","journal-title":"Therapeutic Apheresis & Dialysis"},{"issue":"12","key":"10.1002\/14651858.CD006023.pub3-BIB0193|cit193","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1093\/ndt\/10.12.2321","article-title":"Calcium acetate versus calcium carbonate and erythropoietin dosages in haemodialysis patients","volume":"10","author":"Janssen","year":"1995","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub3-BIB0194|cit194","first-page":"111","article-title":"Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients","volume":"45","author":"Janssen","year":"1996","journal-title":"Clinical Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub3-BIB0195|cit195","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1093\/ndt\/6.2.98","article-title":"Comparison of calcium carbonate and aluminium hydroxide as phosphate binders on biochemical bone markers, PTH(1-84), and bone mineral content in dialysis patients","volume":"6","author":"Jespersen","year":"1991","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Abstracts Issue","key":"10.1002\/14651858.CD006023.pub3-BIB0196|cit196","first-page":"708A","article-title":"Sevelamer attenuates the progression of coronary calcification and serum pentosidine content (an AGE) by HPLC assay in haemodialysis patients [abstract no: SU-PO569]","volume":"18","author":"Kakuta","year":"2007","journal-title":"Journal of the American Society of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub3-BIB0197|cit197","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1053\/j.ajkd.2010.10.055","article-title":"Effect of sevelamer and calcium-based phosphate binders on coronary artery calcification and accumulation of circulating advanced glycation end products in hemodialysis patients.[Erratum appears in Am J Kidney Dis. 2011 May;57(5):804]","volume":"57","author":"Kakuta","year":"2011","journal-title":"American Journal of Kidney Diseases"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub3-BIB0198|cit198","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/j.1744-9987.2012.01071.x","article-title":"Randomized crossover study of the efficacy and safety of sevelamer hydrochloride and lanthanum carbonate in Japanese patients undergoing hemodialysis","volume":"16","author":"Kasai","year":"2012","journal-title":"Therapeutic Apheresis & Dialysis"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub3-BIB0199|cit199","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1177\/089686080602600308","article-title":"Sevelamer hydrochloride versus aluminum hydroxide: Effect on serum phosphorus and lipids in CAPD patients","volume":"26","author":"Katopodis","year":"2006","journal-title":"Peritoneal Dialysis International"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub3-BIB0200|cit200","first-page":"64","article-title":"Efficacy of lanthanum carbonate and calcium carbonate in Korean dialysis patients","volume":"29","author":"Ko","year":"2010","journal-title":"Korean Journal of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub3-BIB0201|cit201","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/nep.12891","article-title":"Efficacy and safety of sucroferric oxyhydroxide compared with sevelamer hydrochloride in Japanese haemodialysis patients with hyperphosphataemia: a randomized, open-label, multicentre, 12-week phase III study","volume":"22","author":"Koiwa","year":"2017","journal-title":"Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub3-BIB0202|cit202","doi-asserted-by":"crossref","first-page":"136","DOI":"10.5414\/CN107362","article-title":"Effect of lanthanum carbonate on phosphate control in continuous ambulatory peritoneal dialysis patients in Korea: a randomized prospective study","volume":"79","author":"Lee","year":"2013","journal-title":"Clinical Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub3-BIB0203|cit203","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s40620-014-0108-6","article-title":"Effect of oral ferric citrate on serum phosphorus in hemodialysis patients: multicenter, randomized, double-blind, placebo-controlled study","volume":"28","author":"Lee","year":"2015","journal-title":"Journal of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub3-BIB0204|cit204","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5414\/CN107630","article-title":"Effect of rosuvastatin and sevelamer on the progression of coronary artery calcification in chronic kidney disease: a pilot study","volume":"80","author":"Lemos","year":"2013","journal-title":"Clinical Nephrology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD006023.pub3-BIB0205|cit205","doi-asserted-by":"crossref","first-page":"iii199","DOI":"10.1093\/ndt\/gfx145.SP273","article-title":"The impact of sevelamer on gut derived uremic toxins levels: results from a multicenter, double blind, randomized, placebo controlled clinical trial [abstract]","volume":"32","author":"Liabeuf","year":"2017","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"12","key":"10.1002\/14651858.CD006023.pub3-BIB0206|cit206","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.2215\/CJN.03030317","article-title":"Randomized clinical trial of sevelamer carbonate on serum klotho and fibroblast growth factor 23 in CKD","volume":"12","author":"Liabeuf","year":"2017","journal-title":"Clinical Journal of The American Society of Nephrology: CJASN"},{"issue":"9","key":"10.1002\/14651858.CD006023.pub3-BIB0207|cit207","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S0929-6646(10)60107-6","article-title":"Benefits of sevelamer on markers of bone turnover in Taiwanese hemodialysis patients","volume":"109","author":"Lin","year":"2010","journal-title":"Journal of the Formosan Medical Association"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub3-BIB0208|cit208","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2165\/11539120-000000000-00000","article-title":"Pleiotropic effects of sevelamer beyond phosphate binding in end-stage renal disease patients: a randomized, open-label, parallel-group study","volume":"31","author":"Lin","year":"2011","journal-title":"Clinical Drug Investigation"},{"key":"10.1002\/14651858.CD006023.pub3-BIB0209|cit209","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s12882-016-0245-3","article-title":"Factors associated with serum fetuin-A concentrations after long-term use of different phosphate binders in hemodialysis patients","volume":"17","author":"Lin","year":"2016","journal-title":"BMC Nephrology"},{"issue":"11","key":"10.1002\/14651858.CD006023.pub3-BIB0210|cit210","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/nep.12319","article-title":"Long-term sevelamer treatment lowers serum fibroblast growth factor 23 accompanied with increasing serum Klotho levels in chronic haemodialysis patients","volume":"19","author":"Lin","year":"2014","journal-title":"Nephrology"},{"key":"10.1002\/14651858.CD006023.pub3-BIB0211|cit211","first-page":"467A","article-title":"Effect of sevelamer on homocysteinemia and lipid profile in patients undergoing maintenance hemodialysis - a randomized clinical trial [abstract no: F-PO610]","volume":"16","author":"Huang","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"issue":"8","key":"10.1002\/14651858.CD006023.pub3-BIB0212|cit212","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1080\/08860220600925388","article-title":"A comparison of sevelamer hydrochloride with calcium acetate on biomarkers of bone turnover in hemodialysis patients","volume":"28","author":"Liu","year":"2006","journal-title":"Renal Failure"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD006023.pub3-BIB0213|cit213","first-page":"ii503","article-title":"A multi-centre, double-blind, randomised, placebo-controlled, multiple fixed-dose study of colestilan (MCI-196) versus placebo in chronic kidney disease stage 5 subjects on dialysis (CKD 5D) with hyperphosphataemia and dyslipidaemia (DL): safety results [abstract no: SAP575]","volume":"27","author":"Dimkovic","year":"2012","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"7","key":"10.1002\/14651858.CD006023.pub3-BIB0214|cit214","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1093\/ndt\/gft064","article-title":"Evaluation of colestilan in chronic kidney disease dialysis patients with hyperphosphataemia and dyslipidaemia: a randomized, placebo-controlled, multiple fixed-dose trial","volume":"28","author":"Locatelli","year":"2013","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"5","key":"10.1002\/14651858.CD006023.pub3-BIB0215|cit215","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1093\/ndt\/gft476","article-title":"The effects of colestilan versus placebo and sevelamer in patients with CKD 5D and hyperphosphataemia: a 1-year prospective randomized study","volume":"29","author":"Locatelli","year":"2014","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD006023.pub3-BIB0216|cit216","doi-asserted-by":"crossref","first-page":"iii679","DOI":"10.1093\/ndt\/gfx179.MP673","article-title":"Efficacy and safety of iron-based phosphate binders, ferric citrate hydrate versus sucroferric oxyhydroxide, on hyperphosphatemia in chronic hemodialysis patients [abstract]","volume":"32","author":"Matsushima","year":"2017","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"9","key":"10.1002\/14651858.CD006023.pub3-BIB0217|cit217","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.2215\/CJN.01650211","article-title":"Effect of phosphate binders on serum inflammatory profile, soluble CD14, and endotoxin levels in hemodialysis patients","volume":"6","author":"Navarro-Gonzalez","year":"2011","journal-title":"Clinical Journal of The American Society of Nephrology: CJASN"},{"key":"10.1002\/14651858.CD006023.pub3-BIB0218|cit218","unstructured":"NCT00542815 A study of MCI-196 in chronic kidney disease stage V subjects on dialysis with hyperphosphatemia ClinicalTrials.gov\/show\/NCT00542815"},{"issue":"5","key":"10.1002\/14651858.CD006023.pub3-BIB0219|cit219","first-page":"870","article-title":"Efficacy and safety of nicotinamide in haemodialysis patients: the NICOREN study","volume":"32","author":"Lenglet","year":"2017","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD006023.pub3-BIB0220|cit220","first-page":"ii229","article-title":"Lanthanum carbonate delays the progression of coronary artery calcification compared with calcium-based phosphate binder in patients on hemodialysis [abstract]","volume":"27","author":"Ohtake","year":"2012","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"5","key":"10.1002\/14651858.CD006023.pub3-BIB0221|cit221","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1177\/1074248413486355","article-title":"Lanthanum carbonate delays progression of coronary artery calcification compared with calcium-based phosphate binders in patients on hemodialysis: a pilot study","volume":"18","author":"Ohtake","year":"2013","journal-title":"Journal of Cardiovascular Pharmacology & Therapeutics"},{"issue":"Suppl 6","key":"10.1002\/14651858.CD006023.pub3-BIB0222|cit222","first-page":"vi183","article-title":"Effective reduction of serum phosphorus using carbonate, with fewer tablets than sevelamer hydrochloride [abstract no: FP486]","volume":"22","author":"Pratt","year":"2007","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1002\/14651858.CD006023.pub3-BIB0223|cit223","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1471-2369-15-71","article-title":"Changes in fibroblast growth factor 23 levels in normophosphatemic patients with chronic kidney disease stage 3 treated with lanthanum carbonate: results of the PREFECT study, a phase 2a, double blind, randomized, placebo-controlled trial","volume":"15","author":"Ure\u00f1a-Torres","year":"2014","journal-title":"BMC Nephrology"},{"key":"10.1002\/14651858.CD006023.pub3-BIB0224|cit224","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2369-12-9","article-title":"A randomized, double-blind, placebo-controlled trial of calcium acetate on serum phosphorus concentrations in patients with advanced non-dialysis-dependent chronic kidney disease","volume":"12","author":"Qunibi","year":"2011","journal-title":"BMC Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub3-BIB0225|cit225","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s10157-017-1504-8","article-title":"Plasma p-cresol lowering effect of sevelamer in non-dialysis CKD patients: evidence from a randomized controlled trial","volume":"22","author":"Riccio","year":"2018","journal-title":"Clinical & Experimental Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub3-BIB0226|cit226","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S0272-6386(89)80052-6","article-title":"Phosphate-binding effects of sucralfate in patients with chronic renal failure","volume":"13","author":"Roxe","year":"1989","journal-title":"American Journal of Kidney Diseases"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub3-BIB0227|cit227","first-page":"130","article-title":"Effect of oral calcium on noninvasive indices of bone formation and bone mass in hemodialysis patients: a randomized double-blind placebo-controlled study","volume":"20","author":"Rudnicki","year":"1994","journal-title":"Mineral & Electrolyte Metabolism"},{"issue":"10","key":"10.1002\/14651858.CD006023.pub3-BIB0228|cit228","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1038\/sj.ki.5002518","article-title":"The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer","volume":"72","author":"Russo","year":"2007","journal-title":"Kidney International"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub3-BIB0229|cit229","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1093\/ndt\/18.3.582","article-title":"Sevelamer hydrochloride with or without alphacalcidol or higher dialysate calcium vs calcium carbonate in dialysis patients: an open-label, randomized study","volume":"18","author":"Sadek","year":"2003","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub3-BIB0230|cit230","first-page":"26","article-title":"Comparison of calcium acetate with calcium carbonate as phosphate binder in patients on maintenance haemodialysis","volume":"19","author":"Saif","year":"2007","journal-title":"Journal of Ayub Medical College, Abbottabad: JAMC"},{"issue":"Abstracts","key":"10.1002\/14651858.CD006023.pub3-BIB0231|cit231","first-page":"7B","article-title":"Early intervention in the CKD-MDB affects vascular function [abstract no: LB-PO3163]","volume":"22","author":"Seifert","year":"2011","journal-title":"Journal of the American Society of Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub3-BIB0232|cit232","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1159\/000353569","article-title":"Effects of phosphate binder therapy on vascular stiffness in early-stage chronic kidney disease","volume":"38","author":"Seifert","year":"2013","journal-title":"American Journal of Nephrology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD006023.pub3-BIB0233|cit233","first-page":"iii196","article-title":"Sevelamer improves serum electrolyte profile, metabolic and cardiovascular markers and survival in ESRD patients on hemodialysis treatment [abstract no: Sa473]","volume":"3","author":"Sezer","year":"2010","journal-title":"NDT Plus"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub3-BIB0234|cit234","first-page":"58","article-title":"Oral nicotinamide reduces serum phosphorus, increases HDL, and induces thrombocytopenia in hemodialysis patients: a double-blind randomized clinical trial","volume":"31","author":"Shahbazian","year":"2011","journal-title":"Nefrologia"},{"issue":"6","key":"10.1002\/14651858.CD006023.pub3-BIB0235|cit235","first-page":"785","article-title":"Efficacy and safety of sevelamer: comparison with calcium carbonate in the treatment of hyperphosphatemia in hemodialysis patients","volume":"25","author":"Shaheen","year":"2004","journal-title":"Saudi Medical Journal"},{"issue":"Suppl 6","key":"10.1002\/14651858.CD006023.pub3-BIB0236|cit236","first-page":"vi245","article-title":"A comparative study of the effects on pulse wave velocity (PWV) in hemodialysis (HD) patients treated by sevelamer with low dose calcium carbonate or calcium carbonate alone [abstract no: SAP245]","volume":"22","author":"Shibata","year":"2007","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1002\/14651858.CD006023.pub3-BIB0237|cit237","unstructured":"Shibata K Iwamoto T Ono S Murakami T Yanagi M Koguchi N A comparative study of the effects on pulse wave velocity (PWV) in hemodialysis (HD) patients treated by sevelamer with low dose calcium carbonate or calcium carbonate alone. Three-years follow up [abstract no: SU500] World Congress of Nephrology; 2009 May 22-26; Milan, Italy 2009"},{"issue":"5","key":"10.1002\/14651858.CD006023.pub3-BIB0238|cit238","doi-asserted-by":"crossref","first-page":"404","DOI":"10.5414\/CNP70404","article-title":"Multicenter prospective randomized, double-blind comparative study between lanthanum carbonate and calcium carbonate as phosphate binders in Japanese hemodialysis patients with hyperphosphatemia","volume":"70","author":"Shigematsu","year":"2008","journal-title":"Clinical Nephrology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006023.pub3-BIB0239|cit239","first-page":"17","article-title":"The SLO-NIACIN trial: a double-blind placebo controlled trial of low dose slow-release niacin to lower phosphate in haemodialysis patients [abstract no: 010]","volume":"18","author":"Tan","year":"2013","journal-title":"Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD006023.pub3-BIB0240|cit240","first-page":"651","article-title":"Effects of lanthanum carbonate on serum calcium and phosphorus of CAPD patients with chronic renal failure receiving calcitriol pulse therapy due to secondary hyperparathyroidism","volume":"14","author":"Song","year":"2014","journal-title":"Chinese Journal of Evidence-Based Medicine"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub3-BIB0241|cit241","doi-asserted-by":"crossref","first-page":"17","DOI":"10.5414\/CN107764","article-title":"The effect of phosphate binders, calcium and lanthanum carbonate on FGF23 levels in chronic kidney disease patients","volume":"80","author":"Soriano","year":"2013","journal-title":"Clinical Nephrology"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD006023.pub3-BIB0242|cit242","first-page":"v95","article-title":"Lanthanum carbonate - a novel phosphate binder in maintenance dialysis patients [abstract no: SP228]","volume":"20","author":"Sikole","year":"2005","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 12","key":"10.1002\/14651858.CD006023.pub3-BIB0243|cit243","first-page":"67","article-title":"The use of lanthanum carbonate as a novel phosphate binder in maintenance dialysis patients [abstract no: M63]","volume":"17","author":"Sikole","year":"2002","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD006023.pub3-BIB0244|cit244","first-page":"685","article-title":"The impact of lanthanum carbonate and calcium carbonate on renal bone disease in dialysis patients - single center experience [abstract no: w436]","volume":"18","author":"Spasovski","year":"2003","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"7","key":"10.1002\/14651858.CD006023.pub3-BIB0245|cit245","first-page":"630","article-title":"The beneficial effect of lanthanum carbonate on low turnover bone disease in dialysis patients [abstract no: P40]","volume":"26","author":"Spasovski","year":"2003","journal-title":"International Journal of Artificial Organs"},{"key":"10.1002\/14651858.CD006023.pub3-BIB0246|cit246","unstructured":"Spasovski G Sikole A Gelev S Masin J Freemont T Webster I The evolution of renal bone disease in dialysis patients - comparative effects of lanthanum carbonate and calcium carbonate treatment [abstract] 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal 2004 105 6"},{"issue":"6 Suppl","key":"10.1002\/14651858.CD006023.pub3-BIB0247|cit247","first-page":"v376","article-title":"Comparative, bone biopsy-based, 3 years follow-up study in dialysis patients during and after 1 year treatment with lanthanum carbonate [abstract no: TO14]","volume":"20","author":"Spasovski","year":"2005","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Oct","key":"10.1002\/14651858.CD006023.pub3-BIB0248|cit248","first-page":"741A","article-title":"The evolution of renal osteodystrophy in dialysis patients: comparative effects of lanthanum carbonate and calcium carbonate [abstract no: SA-PO842]","volume":"16","author":"Spasovski","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub3-BIB0249|cit249","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1046\/j.1492-7535.2003.01235.x","article-title":"Lanthanum carbonate in the management of renal osteodystrophy in dialysis patients [abstract]","volume":"7","author":"Spasovski","year":"2003","journal-title":"Hemodialysis International"},{"issue":"8","key":"10.1002\/14651858.CD006023.pub3-BIB0250|cit250","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1093\/ndt\/gfl146","article-title":"Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow-up","volume":"21","author":"Spasovski","year":"2006","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub3-BIB0253|cit251","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1542-4758.2009.00364.x","article-title":"Long-term effects of magnesium carbonate on coronary artery calcification and bone mineral density in hemodialysis patients: a pilot study","volume":"13","author":"Spiegel","year":"2009","journal-title":"Hemodialysis International"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub3-BIB0251|cit252","first-page":"A56","article-title":"Magnesium carbonate - an effective phosphate binder [abstract no: 152]","volume":"47","author":"Spiegel","year":"2006","journal-title":"American Journal of Kidney Diseases"},{"issue":"6","key":"10.1002\/14651858.CD006023.pub3-BIB0252|cit253","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1053\/j.jrn.2007.08.005","article-title":"Magnesium carbonate is an effective phosphate binder for chronic hemodialysis patients: a pilot study","volume":"17","author":"Spiegel","year":"2007","journal-title":"Journal of Renal Nutrition"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub3-BIB0254|cit254","doi-asserted-by":"crossref","first-page":"A90","DOI":"10.1053\/j.ajkd.2008.02.263","article-title":"Lanthanum carbonate reduces phosphate burden in patients with CKD stages 3 and 4: results from a randomized multicenter trial [abstract no: 252]","volume":"51","author":"Sprague","year":"2008","journal-title":"American Journal of Kidney Diseases"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub3-BIB0255|cit255","doi-asserted-by":"crossref","first-page":"178","DOI":"10.2215\/CJN.02830608","article-title":"Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4: a randomized trial","volume":"4","author":"Sprague","year":"2009","journal-title":"Clinical Journal of The American Society of Nephrology: CJASN"},{"issue":"Abstracts Issue","key":"10.1002\/14651858.CD006023.pub3-BIB0256|cit256","first-page":"927A","article-title":"Hyperphosphatemia in chronic kidney disease stages 3 and 4: findings from a randomized, multi-center trial [abstract no: PUB442]","volume":"18","author":"Sprague","year":"2007","journal-title":"Journal of the American Society of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub3-BIB0257|cit257","doi-asserted-by":"crossref","first-page":"181","DOI":"10.5414\/CN108269","article-title":"Efficacy and safety of lanthanum carbonate in pre-dialysis CKD patients with hyperphosphatemia: a randomized trial","volume":"82","author":"Takahara","year":"2014","journal-title":"Clinical Nephrology"},{"key":"10.1002\/14651858.CD006023.pub3-BIB0258|cit258","unstructured":"Tielmans C Knoop C Doutrelepont JM Timmermans D Even-Adin D Vanherweghem JL Superiority of calcium acetate (ACET) over carbonate (CARB) to bind phosphorus (P) in hemodialysis patients (HDP) [abstract] 11th International Congress of Nephrology; 1990 Jul 15-20; Tokyo, Japan 1990 219A"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub3-BIB0259|cit259","doi-asserted-by":"crossref","first-page":"216","DOI":"10.5414\/CN107257","article-title":"Effect of lanthanum carbonate vs. calcium carbonate on serum calcium in hemodialysis patients: a crossover study","volume":"78","author":"Toida","year":"2012","journal-title":"Clinical Nephrology"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD006023.pub3-BIB0260|cit260","first-page":"70","article-title":"Attenuation of aortic calcification with lanthanum carbonate vs calcium-based phosphate binders in haemodialysis - a randomized controlled trial [abstract no: 167]","volume":"15","author":"Toussaint","year":"2010","journal-title":"Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub3-BIB0261|cit261","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1440-1797.2010.01412.x","article-title":"Attenuation of aortic calcification with lanthanum carbonate versus calcium-based phosphate binders in haemodialysis: a pilot randomized controlled trial","volume":"16","author":"Toussaint","year":"2011","journal-title":"Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub3-BIB0262|cit262","doi-asserted-by":"crossref","first-page":"119","DOI":"10.2215\/CJN.03410708","article-title":"Determination and validation of aortic calcification measurement from lateral bone densitometry in dialysis patients","volume":"4","author":"Toussaint","year":"2009","journal-title":"Clinical Journal of The American Society of Nephrology: CJASN"},{"issue":"11","key":"10.1002\/14651858.CD006023.pub3-BIB0263|cit263","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1007\/s11255-014-0751-9","article-title":"Magnesium retards the progress of the arterial calcifications in hemodialysis patients: a pilot study","volume":"46","author":"Tzanakis","year":"2014","journal-title":"International Urology & Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD006023.pub3-BIB0264|cit264","doi-asserted-by":"crossref","first-page":"934","DOI":"10.2215\/CJN.12891211","article-title":"Effects of sevelamer on HbA1c, inflammation, and advanced glycation end products in diabetic kidney disease","volume":"7","author":"Vlassara","year":"2012","journal-title":"Clinical Journal of The American Society of Nephrology: CJASN"},{"issue":"5","key":"10.1002\/14651858.CD006023.pub3-BIB0265|cit265","doi-asserted-by":"crossref","first-page":"759","DOI":"10.2215\/CJN.07750814","article-title":"Effects of sevelamer carbonate on advanced glycation end products and antioxidant\/pro-oxidant status in patients with diabetic kidney disease","volume":"10","author":"Yubero-Serrano","year":"2015","journal-title":"Clinical Journal of The American Society of Nephrology: CJASN"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub3-BIB0266|cit266","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/1744-9987.12153","article-title":"Evaluation of aortic calcification with lanthanum carbonate vs. calcium-based phosphate binders in maintenance hemodialysis patients with type 2 diabetes mellitus: an open-label randomized controlled trial","volume":"18","author":"Wada","year":"2014","journal-title":"Therapeutic Apheresis & Dialysis"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub3-BIB0267|cit267","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1007\/s11596-015-1461-y","article-title":"Effects of lanthanum carbonate on vascular calcification in elderly maintenance hemodialysis patients","volume":"35","author":"Wang","year":"2015","journal-title":"Journal of Huazhong University of Science and Technology. Medical Sciences"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub3-BIB0268|cit268","doi-asserted-by":"crossref","first-page":"543","DOI":"10.2215\/CJN.05170513","article-title":"Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD","volume":"9","author":"Yokoyama","year":"2014","journal-title":"Clinical Journal of The American Society of Nephrology: CJASN"},{"issue":"5","key":"10.1002\/14651858.CD006023.pub3-BIB0269|cit269","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1093\/ndt\/gft483","article-title":"A randomized trial of JTT-751 versus sevelamer hydrochloride in patients on hemodialysis","volume":"29","author":"Yokoyama","year":"2014","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"5","key":"10.1002\/14651858.CD006023.pub3-BIB0270|cit270","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1177\/089686080902900515","article-title":"The effect of oral niacinamide on plasma phosphorus levels in peritoneal dialysis patients","volume":"29","author":"Young","year":"2009","journal-title":"Peritoneal Dialysis International"},{"issue":"11","key":"10.1002\/14651858.CD006023.pub3-BIB0271|cit271","first-page":"1293","article-title":"Efficacy of sevelamer carbonate for hyperphosphatemia in patients with end-stage renal disease: a randomized controlled trial","volume":"14","author":"Zhao","year":"2014","journal-title":"Chinese Journal of Evidence-Based Medicine"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub3-BIB0272|cit272","first-page":"9","article-title":"The influence of short-term magnesium carbonate treatment on calcium-phosphorus balance in dialysis patients","volume":"64","author":"Zwiech","year":"2011","journal-title":"Wiadomosci Lekarskie"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub3-BIB0273|cit273","doi-asserted-by":"crossref","first-page":"189","DOI":"10.4103\/0971-4065.98754","article-title":"Sevelamer carbonate experience in Indian end stage renal disease patients","volume":"22","author":"Abraham","year":"2012","journal-title":"Indian Journal of Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD006023.pub3-BIB0274|cit274","doi-asserted-by":"crossref","first-page":"934","DOI":"10.4103\/1319-2442.100865","article-title":"Comparison of efficacy of the phosphate binders nicotinic acid and sevelamer hydrochloride in hemodialysis patients","volume":"23","author":"Ahmadi","year":"2012","journal-title":"Saudi Journal of Kidney Diseases & Transplantation"},{"key":"10.1002\/14651858.CD006023.pub3-BIB0275|cit275","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/1744-9987.12202","article-title":"Dose-finding study of bixalomer in patients with chronic kidney disease on hemodialysis with hyperphosphatemia: a double-blind, randomized, placebo-controlled and sevelamer hydrochloride-controlled open-label, parallel group study","volume":"18 Suppl 2","author":"Akizawa","year":"2014","journal-title":"Therapeutic Apheresis & Dialysis"},{"key":"10.1002\/14651858.CD006023.pub3-BIB0276|cit276","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/1471-2369-15-98","article-title":"Effect of chitosan chewing gum on reducing serum phosphorus in hemodialysis patients: a multi-center, randomized, double-blind, placebo-controlled trial","volume":"15","author":"Akizawa","year":"2014","journal-title":"BMC Nephrology"},{"issue":"Sept","key":"10.1002\/14651858.CD006023.pub3-BIB0277|cit277","first-page":"557A","article-title":"Lanthanum carbonate: a novel non-calcaemic phosphate binder in dialysis patients [abstract]","volume":"11","author":"Al-Baaj","year":"2000","journal-title":"Journal of the American Society of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub3-BIB0278|cit278","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1093\/ndt\/gfh693","article-title":"Control of serum phosphate by oral lanthanum carbonate in patients undergoing haemodialysis and continuous ambulatory peritoneal dialysis in a short-term, placebo-controlled study","volume":"20","author":"Al-Baaj","year":"2005","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1002\/14651858.CD006023.pub3-BIB0279|cit279","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1471-2369-14-40","article-title":"Lanthanum carbonate versus placebo for management of hyperphosphatemia in patients undergoing peritoneal dialysis: a subgroup analysis of a phase 2 randomized controlled study of dialysis patients","volume":"14","author":"Hutchison","year":"2013","journal-title":"BMC Nephrology"},{"issue":"9","key":"10.1002\/14651858.CD006023.pub3-BIB0280|cit280","first-page":"A113","article-title":"Lanthanum carbonate: a novel non-calcaemic phosphate binder in dialysis patients. [abstract]","volume":"15","author":"Hutchison","year":"2000","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub3-BIB0281|cit281","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1053\/j.jrn.2004.04.004","article-title":"Calcium-enriched bread for treatment of uremic hyperphosphatemia","volume":"14","author":"Babarykin","year":"2004","journal-title":"Journal of Renal Nutrition"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD006023.pub3-BIB0282|cit282","first-page":"680","article-title":"Role of chetoanalogues on calcium-phosphate metabolism and anemia of haemodialysis patients: a pilot controlled randomized study [abstract]","volume":"18","author":"Bigi","year":"2003","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1002\/14651858.CD006023.pub3-BIB0283|cit283","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/1471-2369-13-49","article-title":"Fibroblast growth factor 23 and parathyroid hormone after treatment with active vitamin D and sevelamer carbonate in patients with chronic kidney disease stage 3b, a randomized crossover trial","volume":"13","author":"Bleskestad","year":"2012","journal-title":"BMC Nephrology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006023.pub3-BIB0284|cit284","first-page":"i156","article-title":"Effect of chitosan loaded chewing gum on serum phosphate in CKD [abstract]","volume":"28","author":"Block","year":"2013","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"1-2","key":"10.1002\/14651858.CD006023.pub3-BIB0285|cit285","first-page":"93","article-title":"Effect of salivary phosphate-binding chewing gum on serum phosphate in chronic kidney disease","volume":"123","author":"Block","year":"2013","journal-title":"Nephron"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub3-BIB0286|cit286","first-page":"348","article-title":"A comparison of phosphorus-chelating effect of calcium carbonate versus calcium acetate before dialysis","volume":"20","author":"Borrego","year":"2000","journal-title":"Nefrologia"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub3-BIB0287|cit287","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/S0272-6386(97)90009-3","article-title":"Poly(allylamine hydrochloride) (RenaGel): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure","volume":"29","author":"Chertow","year":"1997","journal-title":"American Journal of Kidney Diseases"},{"issue":"6","key":"10.1002\/14651858.CD006023.pub3-BIB0288|cit288","doi-asserted-by":"crossref","first-page":"461","DOI":"10.5414\/CNP63461","article-title":"Lanthanum carbonate (Fosrenol) efficacy and tolerability in the treatment of hyperphosphatemic patients with end-stage renal disease","volume":"63","author":"Chiang","year":"2005","journal-title":"Clinical Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub3-BIB0289|cit289","first-page":"142","article-title":"The novel phosphate binder lanthanum carbonate is preferred to conventional agents in a Chinese population [abstract]","volume":"31","author":"Webster","year":"2004","journal-title":"Nephrology Nursing Journal"},{"issue":"Nov","key":"10.1002\/14651858.CD006023.pub3-BIB0290|cit290","first-page":"204A","article-title":"Efficacy and safety of lanthanum carbonate in the treatment of hyperphosphatemia in Chinese chronic renal failure patients [abstract no: F-PO652]","volume":"14","author":"Yang","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 6","key":"10.1002\/14651858.CD006023.pub3-BIB0291|cit291","first-page":"vi362","article-title":"A randomized, double-blind, placebo-controlled, dose-ranging study of the effects of ferric citrate in patients undergoing hemodialysis [abstract no: SaP381]","volume":"22","author":"Chiang","year":"2007","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"6","key":"10.1002\/14651858.CD006023.pub3-BIB0292|cit292","first-page":"674","article-title":"Sevelamer treatment strategy in peritoneal dialysis patients: conventional dose does not make best use of resources","volume":"20","author":"Chow","year":"2007","journal-title":"Journal of Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD006023.pub3-BIB0293|cit293","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1590\/S1516-31802000000600006","article-title":"Calcium acetate versus calcium carbonate in the control of hyperphosphatemia in hemodialysis patients","volume":"118","author":"d'Almeida Filho","year":"2000","journal-title":"Revista Paulista de Medicina [Sao Paulo Medical Journal]"},{"issue":"5","key":"10.1002\/14651858.CD006023.pub3-BIB0294|cit294","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1053\/j.ajkd.2012.11.041","article-title":"Dose-response and efficacy of ferric citrate to treat hyperphosphatemia in hemodialysis patients: a short-term randomized trial","volume":"61","author":"Dwyer","year":"2013","journal-title":"American Journal of Kidney Diseases"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub3-BIB0295|cit295","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s00467-015-3208-1","article-title":"Efficacy and safety of nicotinamide in the management of hyperphosphatemia in pediatric patients on regular hemodialysis","volume":"31","author":"Borolossy","year":"2016","journal-title":"Pediatric Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD006023.pub3-BIB0296|cit296","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/S0272-6386(12)80496-3","article-title":"Calcium acetate control of serum phosphorus in hemodialysis patients","volume":"17","author":"Emmett","year":"1991","journal-title":"American Journal of Kidney Diseases"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub3-BIB0297|cit297","first-page":"449","article-title":"Calcium acetate control of serum phosphorus in hemodialysis patients [abstract]","volume":"37","author":"Emmett","year":"1990","journal-title":"Kidney International"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub3-BIB0298|cit298","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1159\/000188934","article-title":"Intradialytic calcium balances with different calcium dialysate levels. Effects on cardiovascular stability and parathyroid function","volume":"72","author":"Fabrizi","year":"1996","journal-title":"Nephron"},{"issue":"12","key":"10.1002\/14651858.CD006023.pub3-BIB0299|cit299","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1093\/ndt\/gfp372","article-title":"A randomized, crossover design study of sevelamer carbonate powder and sevelamer hydrochloride tablets in chronic kidney disease patients on haemodialysis","volume":"24","author":"Fan","year":"2009","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006023.pub3-BIB0302|cit300","first-page":"A29","article-title":"Lanthanum carbonate (FosrenolTM) significantly reduces serum phosphorus levels and calcium X phosphorus product values in a dose-ranging study [abstract no: PS1-20]","volume":"8","author":"Finn","year":"2003","journal-title":"Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub3-BIB0300|cit301","doi-asserted-by":"crossref","first-page":"193","DOI":"10.5414\/CNP62193","article-title":"Efficacy and safety of lanthanum carbonate for reduction of serum phosphorus in patients with chronic renal failure receiving hemodialysis","volume":"62","author":"Finn","year":"2004","journal-title":"Clinical Nephrology"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD006023.pub3-BIB0301|cit302","first-page":"685","article-title":"Long-term treatment with lanthanum carbonate (Fosrenol) is safe and effective in haemodialysis patients [abstract no:W434]","volume":"18","author":"Finn","year":"2003","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"5","key":"10.1002\/14651858.CD006023.pub3-BIB0303|cit303","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1185\/030079905X41453","article-title":"A long-term, open-label extension study on the safety of treatment with lanthanum carbonate, a new phosphate binder, in patients receiving hemodialysis","volume":"21","author":"Finn","year":"2005","journal-title":"Current Medical Research & Opinion"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD006023.pub3-BIB0304|cit304","first-page":"v93","article-title":"A randomized, cross-over study to compare once a day with three times per day sevelamer dosing [abstract no: SP221]","volume":"20","author":"Fischer","year":"2005","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub3-BIB0305|cit305","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1053\/j.ajkd.2006.05.026","article-title":"Results of a randomized crossover study comparing once daily and thrice-daily sevelamer dosing","volume":"48","author":"Fischer","year":"2006","journal-title":"American Journal of Kidney Diseases"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD006023.pub3-BIB0307|cit306","first-page":"iv147","article-title":"A new formulation of lanthanum carbonate is preferred by patients and physicians [abstract no: SP396]","volume":"21","author":"Mehrotra","year":"2006","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Abstracts","key":"10.1002\/14651858.CD006023.pub3-BIB0308|cit307","first-page":"356A","article-title":"Efficacy and safety of higher-strength lanthanum carbonate [abstract no: F-PO095]","volume":"17","author":"Mehrotra","year":"2006","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD006023.pub3-BIB0309|cit308","first-page":"732A","article-title":"Patient and physician preference and satisfaction with a new formulation of lanthanum carbonate (LC) [abstract no: SA-PO803]","volume":"16","author":"Mehrotra","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstracts","key":"10.1002\/14651858.CD006023.pub3-BIB0310|cit309","first-page":"356A","article-title":"Preference and satisfaction with reformulated higher-dosage strength lanthanum carbonate [abstract no: F-PO094]","volume":"17","author":"Mehrotra","year":"2006","journal-title":"Journal of the American Society of Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD006023.pub3-BIB0306|cit310","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.2215\/CJN.04741107","article-title":"Higher strength lanthanum carbonate provides serum phosphorus control with a low\u00a0tablet burden and is preferred by patients and physicians: a multicenter study","volume":"3","author":"Mehrotra","year":"2008","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub3-BIB0311|cit311","doi-asserted-by":"crossref","first-page":"127","DOI":"10.5414\/NHP35127","article-title":"Efficacy of aluminum hydrochloride and aluminum hydroxide of lowering plasma phosphate concentrations in patients with chronic renal insufficiency","volume":"35","author":"Friedrich","year":"2006","journal-title":"Nieren und Hochdruckkrankheiten"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub3-BIB0312|cit312","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s10157-013-0815-7","article-title":"Efficacy and safety of SBR759, a novel calcium-free, iron (III)-based phosphate binder, versus placebo in chronic kidney disease stage v Japanese patients on maintenance renal replacement therapy","volume":"18","author":"Fukagawa","year":"2014","journal-title":"Clinical & Experimental Nephrology"},{"issue":"Abstracts","key":"10.1002\/14651858.CD006023.pub3-BIB0313|cit313","first-page":"4B","article-title":"A double-blind, randomized, placebo-controlled multicenter trial to compare the phosphate lowering efficacy of different doses of the iron-based phosphate binder SBR759 to placebo [abstract no: LB-PO3152]","volume":"22","author":"Junge","year":"2011","journal-title":"Journal of the American Society of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub3-BIB0314|cit314","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1159\/000431289","article-title":"Randomized, double-blind, placebo-controlled, withdrawal study of colestilan after dose titration in chronic kidney disease dialysis patients with hyperphosphatemia","volume":"130","author":"Hertel","year":"2015","journal-title":"Nephron"},{"issue":"5","key":"10.1002\/14651858.CD006023.pub3-BIB0315|cit315","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1038\/ki.2012.403","article-title":"Oral calcium carbonate affects calcium but not phosphorus balance in stage 3-4 chronic kidney disease","volume":"83","author":"Hill","year":"2013","journal-title":"Kidney International"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub3-BIB0316|cit316","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1542-4758.2010.00509.x","article-title":"Phosphate-binding efficacy of crushed vs. chewed lanthanum carbonate in hemodialysis patients","volume":"15","author":"How","year":"2011","journal-title":"Hemodialysis International"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006023.pub3-BIB0317|cit317","first-page":"i470","article-title":"A randomized, open-label, crossover design study to compare the safety and efficacy of sevelamer carbonate versus calcium carbonate in the treatment of hyperphosphataemia in patients with chronic kidney disease on dialysis [abstract]","volume":"28","author":"Ibrahim","year":"2013","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub3-BIB0318|cit318","doi-asserted-by":"crossref","first-page":"B66","DOI":"10.1053\/j.ajkd.2010.02.144","article-title":"Short-term effect of dietary phosphorus restriction and lanthanum carbonate on FGF23 in chronic kidney disease patients [abstract no: 137]","volume":"55","author":"Isakova","year":"2010","journal-title":"American Journal of Kidney Diseases"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub3-BIB0319|cit319","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1093\/ndt\/gfq419","article-title":"Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease","volume":"26","author":"Isakova","year":"2011","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub3-BIB0320|cit320","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/BF01666818","article-title":"Calcium carbonate as a phosphate binder in dialysis patients: evaluation of an enteric-coated preparation and effect of additional Aluminium hydroxide on hyperaluminaemia","volume":"69","author":"Ittel","year":"1991","journal-title":"Klinische Wochenschrift"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD006023.pub3-BIB0321|cit321","first-page":"686","article-title":"Lanthanum carbonate (fosrenol) causes significant reductions in serum phosphorus and ca x p product in a dose-ranging, placebo-controlled study [abstract no: w437]","volume":"18","author":"Finn","year":"2003","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD006023.pub3-BIB0322|cit322","first-page":"261A","article-title":"Results of a randomized dose-ranging, placebo controlled study of lanthanum carbonate for reduction of serum phosphate in chronic renal failure patients receiving hemodialysis [abstract]","volume":"10","author":"Finn","year":"1999","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD006023.pub3-BIB0323|cit323","first-page":"263A","article-title":"Safety of an investigational phosphate binder (lanthanum carbonate) in hemodialysis patients [abstract]","volume":"10","author":"Joy","year":"1999","journal-title":"Journal of the American Society of Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub3-BIB0324|cit324","first-page":"150","article-title":"Efficacy and tolerability of lanthanum carbonate, a new phosphate binder for the treatment of hyperphosphatemia [abstract]","volume":"30","author":"Finn","year":"2003","journal-title":"Nephrology Nursing Journal"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub3-BIB0325|cit325","first-page":"151","article-title":"Lanthanum carbonate, a novel phosphate binder, is effective and has a good safety profile in the long-term treatment of hyperphosphatemia in end-stage renal disease [abstract]","volume":"30","author":"Finn","year":"2003","journal-title":"Nephrology Nursing Journal"},{"issue":"5","key":"10.1002\/14651858.CD006023.pub3-BIB0326|cit326","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1185\/030079905X41453","article-title":"A long-term, open-label extension study on the safety of treatment with lanthanum carbonate, a new phosphate binder, in patients receiving hemodialysis","volume":"21","author":"Finn","year":"2005","journal-title":"Current Medical Research & Opinion"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub3-BIB0327|cit327","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S0272-6386(03)00554-7","article-title":"Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia","volume":"42","author":"Joy","year":"2003","journal-title":"American Journal of Kidney Diseases"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub3-BIB0328|cit328","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5414\/CN106830","article-title":"Dissociation between progression of coronary artery calcification and endothelial function in hemodialysis patients: a prospective pilot study","volume":"78","author":"Kalil","year":"2012","journal-title":"Clinical Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub3-BIB0329|cit329","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/j.1744-9987.2005.00293.x","article-title":"Sevelamer hydrochloride and calcium bicarbonate reduce serum fibroblast growth factor 23 levels in dialysis patients","volume":"9","author":"Koiwa","year":"2005","journal-title":"Therapeutic Apheresis & Dialysis"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub3-BIB0330|cit330","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/j.1744-9987.2005.00294.x","article-title":"Prospective randomized multicenter trial of sevelamer hydrochloride and calcium carbonate for the treatment of hyperphosphatemia in hemodialysis patients in Japan","volume":"9","author":"Koiwa","year":"2005","journal-title":"Therapeutic Apheresis & Dialysis"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub3-BIB0331|cit331","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s10157-016-1299-z","article-title":"Dose-response efficacy and safety of PA21 in Japanese hemodialysis patients with hyperphosphatemia: a randomized, placebo-controlled, double-blind, Phase II study.[Erratum appears in Clin Exp Nephrol. 2017 Jun;21(3):523; PMID: 27832343]","volume":"21","author":"Koiwa","year":"2017","journal-title":"Clinical & Experimental Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub3-BIB0332|cit332","doi-asserted-by":"crossref","first-page":"A68","DOI":"10.1016\/j.krcp.2012.04.527","article-title":"Fosrenol for enhancing dietary protein intake in hypoalbuminemic dialysis patients (FREDI) study [abstract]","volume":"31","author":"Koontz","year":"2012","journal-title":"Kidney Research & Clinical Practice"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub3-BIB0333|cit333","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1093\/ndt\/gfh632","article-title":"Effect of MCI-196 (colestilan) as a phosphate binder on hyperphosphataemia in haemodialysis patients: a double-blind, placebo-controlled, short-term trial","volume":"20","author":"Kurihara","year":"2005","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Nov","key":"10.1002\/14651858.CD006023.pub3-BIB0334|cit334","first-page":"206A","article-title":"Effect of MCI-196 (colestilan) on hyperphosphatemia in hemodialysis patients [abstract no: F-PO662]","volume":"14","author":"Kurihara","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"10","key":"10.1002\/14651858.CD006023.pub3-BIB0335|cit335","first-page":"e284","article-title":"Changes in serum fibroblast growth factor 23 during the use of calcium carbonate concurrent with calcitriol in stage 3 CKD patients [abstract no: 341]","volume":"33","author":"Lee","year":"2013","journal-title":"Pharmacotherapy"},{"issue":"Oct","key":"10.1002\/14651858.CD006023.pub3-BIB0336|cit336","first-page":"272A","article-title":"MCI-196, a new phosphate binder, has an additional effect on dyslipidemia and uric acid in patients with hyperphosphatemia on hemodialysis [abstract no: F-PO952]","volume":"15","author":"Locatelli","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Oct","key":"10.1002\/14651858.CD006023.pub3-BIB0337|cit337","first-page":"272A","article-title":"MCI-196, a new phosphate binder, reduces hyperphosphatemia in hemodialysis patients: a phase II, dose-finding study [abstract no: F-PO953]","volume":"15","author":"Locatelli","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub3-BIB0338|cit338","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1093\/ndt\/gfp445","article-title":"Effect of MCI-196 on serum phosphate and cholesterol levels in haemodialysis patients with hyperphosphataemia: a double-blind, randomized, placebo-controlled study","volume":"25","author":"Locatelli","year":"2010","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD006023.pub3-BIB0339|cit339","first-page":"v5","article-title":"MCI-196, a new phosphate binder, reduces hyperphosphataemia and lipid levels in patients on regular hemodialysis [abstract no: SO08]","volume":"20","author":"Locatelli","year":"2005","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub3-BIB0340|cit340","first-page":"384","article-title":"Calcium acetate (CaAc), an effective binder of dietary phosphorus (P) in patients with chronic renal failure (CRF) [abstract]","volume":"35","author":"Mai","year":"1989","journal-title":"Kidney International"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub3-BIB0341|cit341","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/ki.1989.247","article-title":"Calcium acetate, an effective phosphorus binder in patients with renal failure","volume":"36","author":"Mai","year":"1989","journal-title":"Kidney International"},{"issue":"6496","key":"10.1002\/14651858.CD006023.pub3-BIB0342|cit342","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1136\/bmj.291.6496.623","article-title":"Suppression of secondary hyperparathyroidism in children with chronic renal failure by high dose phosphate binders: calcium carbonate versus aluminium hydroxide","volume":"291","author":"Mak","year":"1985","journal-title":"British Medical Journal Clinical Research Ed"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub3-BIB0343|cit343","first-page":"797","article-title":"Effect of salmon calcitonin on bone mineral density and calcium-phosphate metabolism in chronic hemodialysis patients with secondary hyperparathyroidism","volume":"112","author":"Matuszkiewicz-Rowinska","year":"2004","journal-title":"Polskie Archiwum Medycyny Wewnetrznej"},{"issue":"Suppl 6","key":"10.1002\/14651858.CD006023.pub3-BIB0344|cit344","first-page":"vi171","article-title":"Iron-magnesium hydroxycarbonate (alpharen): a novel non calcium containing phosphate binder for the treatment of hyperphosphataemia in chronic haemodialysis patients [abstract no: FP452]","volume":"22","author":"McIntyre","year":"2007","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Abstracts","key":"10.1002\/14651858.CD006023.pub3-BIB0345|cit345","first-page":"359A","article-title":"Alpharen is a novel effective non calcium containing phosphate binder for the treatment of hyperphosphataemia in chronic haemodialysis patients [abstract no: F-PO108]","volume":"17","author":"McIntyre","year":"2006","journal-title":"Journal of the American Society of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub3-BIB0346|cit346","doi-asserted-by":"crossref","first-page":"A60","DOI":"10.1053\/j.ajkd.2007.02.148","article-title":"Iron-magnesium hydroxycarbonate (alpharen): a novel non calcium containing phosphate binder for the treatment of hyperphosphataemia in chronic haemodialysis patients [abstract no: 142]","volume":"49","author":"McIntyre","year":"2007","journal-title":"American Journal of Kidney Diseases"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub3-BIB0347|cit347","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2215\/CJN.02630608","article-title":"Iron-magnesium hydroxycarbonate (fermagate): a novel non-calcium-containing phosphate binder for the treatment of hyperphosphatemia in chronic hemodialysis patients","volume":"4","author":"McIntyre","year":"2009","journal-title":"Clinical Journal of The American Society of Nephrology: CJASN"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD006023.pub3-BIB0348|cit348","first-page":"612A","article-title":"Ferric citrate (FC), an alternate phosphorous (PHS)-binder in ESRD patients on hemodialysis (HD) [abstract no: A3098]","volume":"10","author":"Messana","year":"1999","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD006023.pub3-BIB0350|cit349","first-page":"141","article-title":"A randomized, double-blind, placebo-controlled, dose-ranging study using Genz-644470 and sevelamer carbonate in hyperphosphatemic chronic kidney disease patients on hemodialysis","volume":"7","author":"Moustafa","year":"2014","journal-title":"International Journal of Nephrology & Renovascular Disease"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD006023.pub3-BIB0349|cit350","first-page":"iii236","article-title":"A randomized, double-blind, placebo-controlled, dose-ranging study using Genz-644470 and sevelamer carbonate in hyperphosphatemic chronic kidney disease patients on hemodialysis [abstract no: Sa578]","volume":"3","author":"Moustafa","year":"2010","journal-title":"NDT Plus"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD006023.pub3-BIB0351|cit351","first-page":"ii176","article-title":"Dose dependent reduction of cytotoxic advanced glycation endproducts by sevelamer carbonate [abstract]","volume":"27","author":"Striker","year":"2012","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006023.pub3-BIB0352|cit352","first-page":"i488","article-title":"Methylglyoxal (MG) levels are markedly higher in diabetic hemodialysis (HD) patients than non-diabetic HD patients, which may contribute to increased morbidity and mortality in diabetics [abstract no: MP599]","volume":"28","author":"Striker","year":"2013","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1002\/14651858.CD006023.pub3-BIB0353|cit353","unstructured":"Mouzo R Sierra FG Lombardi V Rodriguez J Castro P Alvarez A Effectiveness of sevelamer (SEV) administration according to Hispanic dietary habits and phosphate food content in hemodialysis chronic (HD) patients [abstract] 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal 2004 104"},{"key":"10.1002\/14651858.CD006023.pub3-BIB0354|cit354","unstructured":"NCT00018135 Parathyroid hormone levels in relation to the phosphorus content of meals www.clinicaltrials.gov\/ct2\/show\/NCT00018135"},{"key":"10.1002\/14651858.CD006023.pub3-BIB0355|cit355","unstructured":"Covic A Mircescu G Arterial stiffness and calcifications in haemodialysis patients on sevelamer or calcium acetate www.clinicalTrials.gov\/show\/NCT00364000"},{"key":"10.1002\/14651858.CD006023.pub3-BIB0356|cit356","unstructured":"Taal M Dose ranging study of magnesium iron hydroxycarbonate in haemodialysis subjects with hyperphosphataemia www.clinicalTrials.gov\/show\/NCT00436683"},{"key":"10.1002\/14651858.CD006023.pub3-BIB0357|cit357","unstructured":"Lau A Chewed vs. crushed lanthanum carbonate in hemodialysis patients www.clinicalTrials.gov\/show\/NCT00660530"},{"key":"10.1002\/14651858.CD006023.pub3-BIB0358|cit358","unstructured":"Wang A Sevelamer hydrochloride in peritoneal dialysis patients www.clinicaltrials.gov\/show\/NCT00745589"},{"key":"10.1002\/14651858.CD006023.pub3-BIB0359|cit359","unstructured":"Katanko P Equivalence of calcium acetate oral solution and sevelamer carbonate tablets in hemodialysis patients www.clinicaltrials.gov\/show\/NCT01427907"},{"key":"10.1002\/14651858.CD006023.pub3-BIB0360|cit360","unstructured":"Kim YS Effect of phosphate binders on FGF-23 with concurrent calcitriol www.clinicaltrials.gov\/show\/NCT01748396"},{"key":"10.1002\/14651858.CD006023.pub3-BIB0361|cit361","unstructured":"Floege J Therapeutic equivalence of OsvaRen\u00ae tablets and OsvaRen\u00ae granules www.clinicaltrials.gov\/show\/NCT02027662"},{"key":"10.1002\/14651858.CD006023.pub3-BIB0362|cit362","unstructured":"Block GA A two-arm, open-label, standard of care control evaluation of ferric citrate for the transition from chronic kidney disease stage 4\/5 to chronic kidney stage 5D www.clinicaltrials.gov\/show\/NCT02492620"},{"key":"10.1002\/14651858.CD006023.pub3-BIB0363|cit363","unstructured":"Chen J Study of individualized therapy on hyperphosphatemia in maintenance hemodialysis patients www.clinicaltrials.gov\/show\/NCT02684643"},{"key":"10.1002\/14651858.CD006023.pub3-BIB0364|cit364","unstructured":"Greenbaum LA An open-label, randomised, active-controlled, parallel group, multicentre, phase 3 study to investigate the safety and efficacy of PA21 (Velphoro\u00ae) and calcium acetate (phoslyra\u00ae) in paediatric and adolescent CKD patients with hyperphosphataemia www.clinicaltrials.gov\/show\/NCT02688764"},{"key":"10.1002\/14651858.CD006023.pub3-BIB0365|cit365","unstructured":"NCT03163576 The efficacy and safety of niacin on hyperphosphatemia in end stage renal disease patients undergoing haemodialysis www.clinicaltrials.gov\/show\/NCT03163576"},{"key":"10.1002\/14651858.CD006023.pub3-BIB0366|cit366","unstructured":"Sankyo D A phase 1b study, to assess the safety, tolerability, pharmacodynamics, and pharmacokinetics of repeated doses of DS-2330b alone and when co-administered with sevelamer in patients on chronic hemodialysis www.clinicaltrials.gov\/show\/NCT03305471"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub3-BIB0367|cit367","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1774-9987.2005.00212.x","article-title":"Control of parathyroid function in patients with a short history of hemodialysis","volume":"9","author":"Nishi","year":"2005","journal-title":"Therapeutic Apheresis & Dialysis"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub3-BIB0368|cit368","doi-asserted-by":"crossref","first-page":"286","DOI":"10.2215\/CJN.05420709","article-title":"Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy?","volume":"5","author":"Oliveira","year":"2010","journal-title":"Clinical Journal of The American Society of Nephrology: CJASN"},{"issue":"Abstracts","key":"10.1002\/14651858.CD006023.pub3-BIB0369|cit369","first-page":"532A","article-title":"Sevelamer (SEV), but not calcium acetate (CA), lowers fibroblast growth factor 23 (FGF23) in chronic kidney disease (CKD) patients [abstract no: SA-PO862]","volume":"18","author":"Oliveira","year":"2007","journal-title":"Journal of the American Society of Nephrology"},{"issue":"10","key":"10.1002\/14651858.CD006023.pub3-BIB0370|cit370","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1093\/ndt\/gft234","article-title":"Disturbances of Wnt\/beta-catenin pathway and energy metabolism in early CKD: effect of phosphate binders","volume":"28","author":"Oliveira","year":"2013","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub3-BIB0371|cit371","doi-asserted-by":"crossref","first-page":"36","DOI":"10.2215\/CJN.03591006","article-title":"The OPTIMA study: assessing a new cinacalcet (Sensipar\/Mimpara) treatment algorithm for secondary hyperparathyroidism","volume":"3","author":"Messa","year":"2008","journal-title":"Clinical Journal of The American Society of Nephrology: CJASN"},{"issue":"Abstracts","key":"10.1002\/14651858.CD006023.pub3-BIB0372|cit372","first-page":"924A","article-title":"Does simultaneous administration of sevelamer and calcium carbonate decrease phosphate-binding capacity? [abstract no: PUB429]","volume":"18","author":"Ouellet","year":"2007","journal-title":"Journal of the American Society of Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub3-BIB0373|cit373","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/j.1744-9987.2009.00748.x","article-title":"Does concomitant administration of sevelamer and calcium carbonate modify the control of phosphatemia?","volume":"14","author":"Ouellet","year":"2010","journal-title":"Therapeutic Apheresis & Dialysis"},{"key":"10.1002\/14651858.CD006023.pub3-BIB0374|cit374","unstructured":"Pai P Ross C Wilkie M Warwick G Chapman A McIntyre C Fermagate (Alpharen) provides long term effective control of serum phosphate combined with good tolerability [abstract no: SU609] World Congress of Nephrology; 2009 May 22-26; Milan, Italy 2009"},{"issue":"Abstracts Issue","key":"10.1002\/14651858.CD006023.pub3-BIB0375|cit375","first-page":"732A","article-title":"Fermagate (AlpharenT): a novel anion exchange compound, effectively controls hyperphosphatemia in patients on hemodialysis [abstract no: SA-PO2751]","volume":"19","author":"Pai","year":"2008","journal-title":"Journal of the American Society of Nephrology"},{"issue":"8","key":"10.1002\/14651858.CD006023.pub3-BIB0377|cit376","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1093\/ndt\/9.8.1121","article-title":"Calcium acetate versus calcium carbonate as phosphate-binding agents in chronic haemodialysis","volume":"9","author":"Pflanz","year":"1994","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"11","key":"10.1002\/14651858.CD006023.pub3-BIB0376|cit377","first-page":"1301","article-title":"Calcium acetate versus calcium carbonate as phosphate-binding agents in chronic haemodialysis [abstract]","volume":"8","author":"Pflanz","year":"1993","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"5-6","key":"10.1002\/14651858.CD006023.pub3-BIB0378|cit378","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1159\/000065273","article-title":"Metabolic and skeletal effects of low and high doses of calcium acetate in patients with preterminal chronic renal failure","volume":"22","author":"Phelps","year":"2002","journal-title":"American Journal of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub3-BIB0379|cit379","doi-asserted-by":"crossref","first-page":"191","DOI":"10.5414\/CN108227","article-title":"Use of sevelamer to examine the role of intraluminal phosphate in the pathogenesis of secondary hyperparathyroidism","volume":"82","author":"Phelps","year":"2014","journal-title":"Clinical Nephrology"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD006023.pub3-BIB0380|cit380","first-page":"v80","article-title":"Alfacalcidol is essential for bone mineral density in chronic renal failure [abstract no: SP184]","volume":"20","author":"Przedlacki","year":"2005","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub3-BIB0381|cit381","first-page":"341","article-title":"Calcium acetate versus calcium carbonate as phosphorus binders in patients on chronic haemodialysis: a controlled study","volume":"8","author":"Ring","year":"1993","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub3-BIB0382|cit382","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1159\/000187515","article-title":"Oral calcium effectively reduces parathyroid hormone levels in hemodialysis patients: a randomized double-blind placebo-controlled study","volume":"65","author":"Rudnicki","year":"1993","journal-title":"Nephron"},{"issue":"Abstracts Issue","key":"10.1002\/14651858.CD006023.pub3-BIB0383|cit383","first-page":"936A","article-title":"Randomzied, open-label, cross-over study to assess the potential pharmacokinetic interaction of warfarin and sevelamer carbonate [abstract no: PUB555]","volume":"19","author":"Ruff","year":"2008","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub3-BIB0384|cit384","first-page":"328","article-title":"Prospective assessment of aluminum retention in dialyzed patients given calcium carbonate or aluminum hydroxide [abstract]","volume":"37","author":"Goodman","year":"1990","journal-title":"Kidney International"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub3-BIB0385|cit385","first-page":"451","article-title":"Prospective trial of calcium carbonate versus aluminum hydroxide with oral calcitriol therapy in renal osteodystrophy [abstract]","volume":"37","author":"Salusky","year":"1990","journal-title":"Kidney International"},{"key":"10.1002\/14651858.CD006023.pub3-BIB0386|cit386","unstructured":"Salusky IB Foley J Goodman WG Calcium carbonate versus aluminum hydroxide with oral calcitriol therapy in pediatric renal osteodystrophy [abstract] 11th International Congress of Nephrology; 1990 Jul 15-20; Tokyo, Japan 1990 416A"},{"issue":"8","key":"10.1002\/14651858.CD006023.pub3-BIB0387|cit387","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1056\/NEJM199102213240804","article-title":"Aluminum accumulation during treatment with aluminum hydroxide and dialysis in children and young adults with chronic renal disease","volume":"324","author":"Salusky","year":"1991","journal-title":"New England Journal of Medicine"},{"issue":"Abstracts","key":"10.1002\/14651858.CD006023.pub3-BIB0388|cit388","first-page":"134A","article-title":"Differential effect of doxercalciferol and calcitriol on skeletal lesions of secondary hyperparathyroidism [abstract no: TH-PO133]","volume":"17","author":"Pereira","year":"2006","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Nov","key":"10.1002\/14651858.CD006023.pub3-BIB0389|cit389","first-page":"202A","article-title":"Skeletal response to the treatment of secondary hyperparathyroidism: a comparison between calcitriol and 1-Alpha-D2 [abstract no: F-PO643]","volume":"14","author":"Salusky","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Oct","key":"10.1002\/14651858.CD006023.pub3-BIB0390|cit390","first-page":"281A","article-title":"Prospective comparison of calcium-based binder versus sevelamer HCL on the control of the skeletal lesions of secondary hyperparathyroidism [abstract no: F-PO989]","volume":"15","author":"Salusky","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"issue":"8","key":"10.1002\/14651858.CD006023.pub3-BIB0391|cit391","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1681\/ASN.2004100885","article-title":"Sevelamer controls parathyroid hormone-induced bone disease as efficiently as calcium carbonate without increasing serum calcium levels during therapy with active vitamin D sterols","volume":"16","author":"Salusky","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Nov","key":"10.1002\/14651858.CD006023.pub3-BIB0392|cit392","first-page":"206A","article-title":"A prospective assessment of sevelamer hydrochloride versus calcium carbonate in dialyzed children [abstract no: F-PO661]","volume":"14","author":"Salusky","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstracts","key":"10.1002\/14651858.CD006023.pub3-BIB0393|cit393","first-page":"134A","article-title":"Effects of vitamin D therapy on FGF-23, PTH and the skeletal lesions of secondary hyperparathyroidism [abstract no: TH-PO132]","volume":"17","author":"Wesseling","year":"2006","journal-title":"Journal of the American Society of Nephrology"},{"issue":"7","key":"10.1002\/14651858.CD006023.pub3-BIB0394|cit394","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1007\/s00467-009-1143-8","article-title":"Response of different PTH assays to therapy with sevelamer or CaCO3 and active vitamin D sterols","volume":"24","author":"Wesseling-Perry","year":"2009","journal-title":"Pediatric Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub3-BIB0395|cit395","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/ki.2010.352","article-title":"Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism","volume":"79","author":"Wesseling-Perry","year":"2011","journal-title":"Kidney International"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub3-BIB0396|cit396","doi-asserted-by":"crossref","first-page":"187","DOI":"10.4103\/0253-7613.56074","article-title":"Effect of lanthanum carbonate and calcium acetate in the treatment of hyperphosphatemia in patients of chronic kidney disease","volume":"41","author":"Scaria","year":"2009","journal-title":"Indian Journal of Pharmacology"},{"issue":"8","key":"10.1002\/14651858.CD006023.pub3-BIB0397|cit397","first-page":"734","article-title":"The effect of calcium acetate and calcitriol on the calcium and phosphorus metabolism in haemodialysis patients [abstract]","volume":"5","author":"Schaefer","year":"1990","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub3-BIB0398|cit398","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1093\/ndt\/6.3.170","article-title":"The treatment of uraemic hyperphosphataemia with calcium acetate and calcium carbonate: a comparative study","volume":"6","author":"Schaefer","year":"1991","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1002\/14651858.CD006023.pub3-BIB0399|cit399","unstructured":"Sechet A Abi Ghanem O Said S Rasombolobna M Oualim Z Moriniere P Role of administration schedule in relation to meal on CaCO3 efficiency in controlling hyperphosphatemia in dialysis patients [abstract] 35th Congress. European Renal Association. European Dialysis and Transplantation Association; 1998 Jun 6-9; Rimini, Italy 1998 38"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub3-BIB0400|cit400","first-page":"209","article-title":"Role of the time of administration of calcium carbonate (before or during mealtime) in the control of hyperphosphatemia in patients on maintenance hemodialysis","volume":"20","author":"Sechet","year":"1999","journal-title":"Nephrologie"},{"issue":"7","key":"10.1002\/14651858.CD006023.pub3-BIB0401|cit401","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1046\/j.1525-1594.1998.06199.x","article-title":"Role of calcium carbonate administration timing in relation to food intake on its efficiency in controlling hyperphosphatemia in patients on maintenance dialysis","volume":"22","author":"Sechet","year":"1998","journal-title":"Artificial Organs"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub3-BIB0402|cit402","first-page":"213","article-title":"Inhibition of gastric secretion by omeprazole and efficacy of calcium carbonate in the control of hyperphosphatemia in patients on maintenance hemodialysis","volume":"20","author":"Sechet","year":"1999","journal-title":"Nephrologie"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub3-BIB0403|cit403","first-page":"140","article-title":"Is sevelamer hydrocloride as effective as calcium carbonate for reduction of serum phosphorus in hemodialysis patients? [abstract]","volume":"16","author":"Seferi","year":"2012","journal-title":"Hemodialysis International"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD006023.pub3-BIB0404|cit404","first-page":"772A","article-title":"The vitamin D therapy alone should be selected in pre-dialysis renal failure patients with secondary hyperparathyroidism, instead of the combination therapy with vitamin D and calcium [abstract]","volume":"12","author":"Shigematsu","year":"2001","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstracts","key":"10.1002\/14651858.CD006023.pub3-BIB0405|cit405","first-page":"887A","article-title":"Lanthanum carbonate is effective enough to control serum P level in line with K\/DOQI target without Ca load in Japanese CKD5 patients undergoing hemodialysis [abstract no: PUB337]","volume":"17","author":"Shigematsu","year":"2006","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub3-BIB0406|cit406","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1744-9987.2007.00541.x","article-title":"Lanthanum carbonate effectively controls serum phosphate without affecting serum calcium levels in patients undergoing hemodialysis","volume":"12","author":"Shigematsu","year":"2008","journal-title":"Therapeutic Apheresis & Dialysis"},{"issue":"9","key":"10.1002\/14651858.CD006023.pub3-BIB0407|cit407","first-page":"1807","article-title":"Niceritrol decreases serum phosphate levels in hemodialysis patients - a randomized, double blind, crossover study [abstract no: A2803]","volume":"7","author":"Shimoda","year":"1996","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub3-BIB0408|cit408","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1093\/ndt\/gfs405","article-title":"Responsiveness of FGF-23 and mineral metabolism to altered dietary phosphate intake in chronic kidney disease (CKD): results of a randomized trial","volume":"28","author":"Sigrist","year":"2013","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub3-BIB0409|cit409","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/sj.ki.5001932","article-title":"Cognitive function in Stage 5 chronic kidney disease patients on hemodialysis: no adverse effects of lanthanum carbonate compared with standard phosphate-binder therapy","volume":"71","author":"Altmann","year":"2007","journal-title":"Kidney International."},{"key":"10.1002\/14651858.CD006023.pub3-BIB0410|cit410","first-page":"272A","article-title":"Lanthanum carbonate has shown no negative effects on cognitive function compared with standard therapy: results from a 2-year study [abstract no: F-PO950]","volume":"15","author":"Altmann","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD006023.pub3-BIB0411|cit411","first-page":"v86","article-title":"25-hydroxyvitamin D and 1,25-dihydroxyvitamin D deficiency in stage V chronic kidney disease patients on hemodialysis [abstract no: SP201]","volume":"20","author":"Finn","year":"2005","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1002\/14651858.CD006023.pub3-BIB0412|cit412","first-page":"765A","article-title":"Lanthanum carbonate versus standard therapy: effects on hematological and biochemical parameters [abstract no: SA-PO951]","volume":"16","author":"Finn","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD006023.pub3-BIB0413|cit413","first-page":"764A","article-title":"No evidence for hepatotoxicity after 2 years of lanthanum carbonate therapy [abstract no: SA-PO950]","volume":"16","author":"Finn","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006023.pub3-BIB0416|cit414","first-page":"A29","article-title":"Lanthanum carbonate (FosrenolTM), a novel phosphate binder, is safe and effective in the long term treatment of hyperphosphatemia in end-stage renal disease [abstract no: PS1-21]","volume":"8","author":"Finn","year":"2003","journal-title":"Nephrology"},{"issue":"Oct","key":"10.1002\/14651858.CD006023.pub3-BIB0417|cit415","first-page":"763A","article-title":"The new phosphate-binding agent lanthanum carbonate: further evidence of long-term (2-year) efficacy and safety [abstract no: PUB006]","volume":"15","author":"Finn","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Nov","key":"10.1002\/14651858.CD006023.pub3-BIB0415|cit416","first-page":"764A","article-title":"Lanthanum carbonate vs. standard therapy in hyperphosphatemia: interim findings from a 2-year safety and outcomes study [abstract no: SU-PO1040]","volume":"14","author":"Finn","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD006023.pub3-BIB0414|cit417","first-page":"686","article-title":"A long-term (2-year) assessment of the safety and efficacy of lanthanum carbonate (fosrenol), a non-calcium, non-aluminium phosphate binder for the treatment of hyperphosphataemia [abstract no: W438]","volume":"18","author":"Finn","year":"2003","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub3-BIB0418|cit418","doi-asserted-by":"crossref","first-page":"191","DOI":"10.5414\/CNP65191","article-title":"Lanthanum carbonate versus standard therapy for the treatment of hyperphosphatemia: safety and efficacy in chronic maintenance hemodialysis patients","volume":"65","author":"Finn","year":"2006","journal-title":"Clinical Nephrology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006023.pub3-BIB0419|cit419","first-page":"A297","article-title":"A 2-year randomized, comparator-controlled trial investigating the effect of lanthanum carbonate on bone [abstract no: W-PO40066]","volume":"10","author":"Malluche","year":"2005","journal-title":"Nephrology"},{"issue":"Oct","key":"10.1002\/14651858.CD006023.pub3-BIB0420|cit420","first-page":"271A","article-title":"Lanthanum carbonate and bone: no adverse effects observed after 1 year of treatment in a randomized, comparator-controlled trial [abstract no: F-PO945]","volume":"15","author":"Malluche","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub3-BIB0421|cit421","doi-asserted-by":"crossref","first-page":"A58","DOI":"10.1053\/j.ajkd.2007.02.139","article-title":"Lanthanum carbonate vs standard phosphate binder therapy: evolution of renal osteodystrophy over 1 and 2 years of treatment [abstract no: 133]","volume":"49","author":"Malluche","year":"2007","journal-title":"American Journal of Kidney Diseases"},{"issue":"Abstracts","key":"10.1002\/14651858.CD006023.pub3-BIB0422|cit422","first-page":"359A","article-title":"Renal osteodystrophy: comparison of evolution over 1 and 2 years during treatment with lanthanum carbonate or standard phosphate binders [abstract no: F-PO107]","volume":"17","author":"Malluche","year":"2006","journal-title":"Journal of the American Society of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub3-BIB0423|cit423","first-page":"284","article-title":"Improvements in renal osteodystrophy in patients treated with lanthanum carbonate for two years","volume":"70","author":"Malluche","year":"2008","journal-title":"Clinical Nephrology"},{"issue":"Suppl 6","key":"10.1002\/14651858.CD006023.pub3-BIB0424|cit424","first-page":"vi171","article-title":"Is 1 year sufficient to observe changes in renal osteodystrophy? Evaluation of serial bone biopsies [abstract no: FP450]","volume":"22","author":"Pratt","year":"2007","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Abstracts Issue","key":"10.1002\/14651858.CD006023.pub3-BIB0425|cit425","first-page":"320A","article-title":"Retrospective outcomes analyses of a 2-year comparative study of lanthanum carbonate vs standard therapy [abstract no: TH-PO928]","volume":"19","author":"Wilson","year":"2008","journal-title":"Journal of the American Society of Nephrology"},{"issue":"12","key":"10.1002\/14651858.CD006023.pub3-BIB0426|cit426","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1185\/03007990903399398","article-title":"Assessment of survival in a 2-year comparative study of lanthanum carbonate versus standard therapy","volume":"25","author":"Wilson","year":"2009","journal-title":"Current Medical Research & Opinion"},{"key":"10.1002\/14651858.CD006023.pub3-BIB0427|cit427","unstructured":"Krause R Sprague S Zhang P Qiu P Ross E Lanthanum carbonate provides greater phosphate reduction than sevelamer hydrochloride over a 4 week treatment period in patients on dialysis [abstract no: SU579] World Congress of Nephrology; 2009 May 22-26; Milan, Italy 2009"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub3-BIB0428|cit428","doi-asserted-by":"crossref","first-page":"252","DOI":"10.5414\/CNP72252","article-title":"Lanthanum carbonate vs sevelamer hydrochloride for the reduction of serum phosphorus in hemodialysis patients: a crossover study","volume":"72","author":"Sprague","year":"2009","journal-title":"Clinical Nephrology"},{"issue":"Abstracts Issue","key":"10.1002\/14651858.CD006023.pub3-BIB0429|cit429","first-page":"721A","article-title":"Nested cross-sectional analysis of baseline date from the Sevelamer hydrochloride and Ultrasound-Measured femoral and carotid intima Media thickness progression in End stage Renal disease: SUMMER [abstract no: SA-PO2704]","volume":"19","author":"Boaz","year":"2008","journal-title":"Journal of the American Society of Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD006023.pub3-BIB0430|cit430","doi-asserted-by":"crossref","first-page":"449","DOI":"10.5414\/CN108067","article-title":"C-reactive protein and carotid and femoral intima media thickness: predicting inflammation","volume":"80","author":"Boaz","year":"2013","journal-title":"Clinical Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub3-BIB0431|cit431","first-page":"c83","article-title":"Effect of sevelamer hydrochloride exposure on carotid intima media thickness in hemodialysis patients","volume":"117","author":"Boaz","year":"2011","journal-title":"Nephron"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub3-BIB0432|cit432","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s11255-007-9300-0","article-title":"Magnesium carbonate for phosphate control in patients on hemodialysis. A randomized controlled trial","volume":"40","author":"Tzanakis","year":"2008","journal-title":"International Urology & Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub3-BIB0433|cit433","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1177\/039463201402700105","article-title":"Clinical efficacy, safety and anti-inflammatory activity of two sevelamer tablet forms in patients on low-flux hemodialysis","volume":"27","author":"Tzanno-Martins","year":"2014","journal-title":"International Journal of Immunopathology & Pharmacology"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub3-BIB0434|cit434","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/hdi.12487","article-title":"Adherence rates to ferric citrate as compared to active control in patients with end stage kidney disease on dialysis","volume":"21","author":"Jalal","year":"2017","journal-title":"Hemodialysis International"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub3-BIB0435|cit435","doi-asserted-by":"crossref","first-page":"A45","DOI":"10.1053\/j.ajkd.2015.02.123","article-title":"Adherence rates and predictors of adherence to ferric citrate as compared to active control in end stage kidney disease [abstract]","volume":"65","author":"Jalal","year":"2015","journal-title":"American Journal of Kidney Diseases"},{"issue":"Abstracts","key":"10.1002\/14651858.CD006023.pub3-BIB0436|cit436","first-page":"751","article-title":"Ferric citrate binds phosphorus, delivers iron, and reduces IV iron and erythropoietic stimulating agent use in end-stage renal disease [abstract no: SA-PO542]","volume":"24","author":"Lewis","year":"2013","journal-title":"Journal of the American Society of Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub3-BIB0437|cit437","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1681\/ASN.2014020212","article-title":"Ferric citrate controls phosphorus and delivers iron in patients on dialysis","volume":"26","author":"Lewis","year":"2015","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstracts","key":"10.1002\/14651858.CD006023.pub3-BIB0438|cit438","first-page":"880A","article-title":"Ferric citrate (phosphate binder): effects on serum iron and other parameters in ESRD patients [abstract no: PUB306]","volume":"17","author":"Niecestro","year":"2006","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD006023.pub3-BIB0439|cit439","unstructured":"Niecestro RM Ferric citrate for the treatment of hyperphosphatemia in ESRD [abstract no: S-PO-0416] 4th World Congress of Nephrology.19th International Congress of the International Society of Nephrology (ISN); 2007 Apr 21-25; Rio de Janeiro, Brazil 2007 161"},{"issue":"5","key":"10.1002\/14651858.CD006023.pub3-BIB0440|cit440","doi-asserted-by":"crossref","first-page":"A118","DOI":"10.1053\/j.ajkd.2014.01.438","article-title":"Phosphorus binding with ferric citrate is associated with fewer hospitalizations and reduced hospitalization costs [abstract]","volume":"63","author":"Rodby","year":"2014","journal-title":"American Journal of Kidney Diseases"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub3-BIB0441|cit441","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1586\/14737167.2015.995169","article-title":"Phosphorus binding with ferric citrate is associated with fewer hospitalizations and reduced hospitalization costs","volume":"15","author":"Rodby","year":"2015","journal-title":"Expert Review of Pharmacoeconomics & Outcomes Research"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub3-BIB0442|cit442","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s40268-015-0103-y","article-title":"Ferric citrate, an iron-based phosphate binder, reduces health care costs in patients on dialysis based on randomized clinical trial data","volume":"15","author":"Rodby","year":"2015","journal-title":"Drugs in R & D"},{"issue":"5","key":"10.1002\/14651858.CD006023.pub3-BIB0443|cit443","doi-asserted-by":"crossref","first-page":"A102","DOI":"10.1053\/j.ajkd.2014.01.351","article-title":"Oral ferric citrate (FC) eliminates the need for intravenous (IV) iron in dialysis patients [abstract]","volume":"63","author":"Sika","year":"2014","journal-title":"American Journal of Kidney Diseases"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub3-BIB0444|cit444","doi-asserted-by":"crossref","first-page":"A78","DOI":"10.1053\/j.ajkd.2015.02.257","article-title":"Iron stores are increased within the first 24 weeks and maintained for 80 additional weeks with longterm use of oral ferric citrate (FC) as a phosphate binder [abstract]","volume":"65","author":"Sika","year":"2015","journal-title":"American Journal of Kidney Diseases"},{"issue":"Abstracts","key":"10.1002\/14651858.CD006023.pub3-BIB0445|cit445","first-page":"751A","article-title":"Ferric citrate as a phosphate binder has a safety profile similar to sevelamer carbonate and calcium acetate [abstract no: SA-PO540]","volume":"24","author":"Sika","year":"2013","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstracts","key":"10.1002\/14651858.CD006023.pub3-BIB0446|cit446","first-page":"221a","article-title":"Ferric citrate as a phosphate binder reduces IV iron and erythropoietin stimulating agent (ESA) use [abstract no: TH-PO521]","volume":"24","author":"Umanath","year":"2013","journal-title":"Journal of the American Society of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub3-BIB0447|cit447","doi-asserted-by":"crossref","first-page":"124","DOI":"10.5414\/CN108924","article-title":"The safety of achieved iron stores and their effect on IV iron and ESA use: post-hoc results from a randomized trial of ferric citrate as a phosphate binder in dialysis","volume":"87","author":"Umanath","year":"2017","journal-title":"Clinical Nephrology"},{"issue":"10","key":"10.1002\/14651858.CD006023.pub3-BIB0448|cit448","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1681\/ASN.2014080842","article-title":"Ferric citrate reduces intravenous iron and erythropoiesis-stimulating agent use in ESRD","volume":"26","author":"Umanath","year":"2015","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstracts","key":"10.1002\/14651858.CD006023.pub3-BIB0449|cit449","first-page":"713A","article-title":"Achieved iron stores and clinical outcomes in a trial of ferric citrate as a phosphate binder [abstract no: SA-PO382]","volume":"24","author":"Umanath","year":"2013","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub3-BIB0450|cit450","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.1542-4758.2012.00711.x","article-title":"Rationale and study design of a three-period, 58-week trial of ferric citrate as a phosphate binder in patients with ESRD on dialysis","volume":"17","author":"Umanath","year":"2013","journal-title":"Hemodialysis International"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub3-BIB0451|cit451","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1053\/j.ajkd.2015.03.013","article-title":"The phosphate binder ferric citrate and mineral metabolism and inflammatory markers in maintenance dialysis patients: results from prespecified analyses of a randomized clinical trial","volume":"66","author":"Buren","year":"2015","journal-title":"American Journal of Kidney Diseases"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub3-BIB0452|cit452","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1159\/000188317","article-title":"Comparison of three formulations of calcium acetate tablets to evaluate tolerance and control of hyperphosphatemia in patients with chronic renal failure","volume":"68","author":"Bergh","year":"1994","journal-title":"Nephron"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub3-BIB0453|cit453","first-page":"A60","article-title":"Lanthanum carbonate allows for a lower tablet burden to control serum phosphorus levels [abstract no: 167]","volume":"47","author":"Vemuri","year":"2006","journal-title":"American Journal of Kidney Diseases"},{"issue":"6","key":"10.1002\/14651858.CD006023.pub3-BIB0454|cit454","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1111\/1744-9987.12178","article-title":"Effect of calcium carbonate combined with calcitonin on hypercalcemia in hemodialysis patients","volume":"18","author":"Wei","year":"2014","journal-title":"Therapeutic Apheresis & Dialysis"},{"key":"10.1002\/14651858.CD006023.pub3-BIB0455|cit455","first-page":"47A","article-title":"Skeletal response to phosphate binders and intermittent oral vitamin D in dialyzed children with secondary hyperparathyroidism [abstract no: F-FC044]","volume":"16","author":"Hernandez","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD006023.pub3-BIB0456|cit456","first-page":"739A","article-title":"Comparison between first and second generation PTH assays as predictors of bone turnover during treatment of secondary hyperparathyroidism in dialyzed children [abstract no: SA-PO833]","volume":"16","author":"Salusky","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Oct","key":"10.1002\/14651858.CD006023.pub3-BIB0457|cit457","first-page":"279A","article-title":"Similar predictive value of bone turnover by first and second generation PTH assays during treatment of secondary hyperparthyroidism in dialyzed children [abstract no: F-PO980]","volume":"15","author":"Wesseling","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub3-BIB0458|cit458","doi-asserted-by":"crossref","first-page":"A27","DOI":"10.1053\/j.ajkd.2012.02.058","article-title":"Iron-based phosphate binder PA21: Effective and well tolerated in CKD hemodialysis patients [abstract]","volume":"59","author":"Chonchol","year":"2012","journal-title":"American Journal of Kidney Diseases"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub3-BIB0459|cit459","doi-asserted-by":"crossref","first-page":"280","DOI":"10.2215\/CJN.08230811","article-title":"Randomized clinical trial of the iron-based phosphate binder PA21 in hemodialysis patients","volume":"8","author":"Wuthrich","year":"2013","journal-title":"Clinical Journal of The American Society of Nephrology: CJASN"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD006023.pub3-BIB0460|cit460","first-page":"iii230","article-title":"The effect of PA21, an oral iron based phosphate binder, on the reduction of hyperphosphatemia in hemodialysis-dependent chronic kidney disease (HD-CKD) patients [abstract no: Sa563]","volume":"3","author":"Wuthrich","year":"2010","journal-title":"NDT Plus"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD006023.pub3-BIB0461|cit461","first-page":"ii153","article-title":"PA21: An effective and well tolerated iron-based phosphate binder for haemodialysis patients, including those with diabetes [abstract]","volume":"27","author":"Wuthrich","year":"2012","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1002\/14651858.CD006023.pub3-BIB0462|cit462","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1471-2369-14-29","article-title":"Lanthanum carbonate for the treatment of hyperphosphatemia in CKD 5D: multicenter, double blind, randomized, controlled trial in mainland China","volume":"14","author":"Xu","year":"2013","journal-title":"BMC Nephrology"},{"key":"10.1002\/14651858.CD006023.pub3-BIB0463|cit463","unstructured":"Yang WC Yang CS Hou CC Wu TH Cheng YR Young EW An open-label, crossover study of a new phosphate binding agent in hemodialysis patients: ferric citrate [abstract] 8th Asian Pacific Congress of Nephrology; 2000 Mar 26-30; Taipei, Taiwan 2000 187"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub3-BIB0464|cit464","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1093\/ndt\/17.2.265","article-title":"An open-label, crossover study of a new phosphate-binding agent in haemodialysis patients: ferric citrate","volume":"17","author":"Yang","year":"2002","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"5","key":"10.1002\/14651858.CD006023.pub3-BIB0465|cit465","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1159\/000344008","article-title":"Effect of oral JTT-751 (ferric citrate) on hyperphosphatemia in hemodialysis patients: results of a randomized, double-blind, placebo-controlled trial","volume":"36","author":"Yokoyama","year":"2012","journal-title":"American Journal of Nephrology"},{"key":"10.1002\/14651858.CD006023.pub3-BIB0466|cit466","unstructured":"Roe S Efficacy and safety study of magnesium iron hydroxycarbonate for the reduction of high blood phosphate in hemodialysis patients www.clinicalTrials.gov\/show\/NCT00317694"},{"key":"10.1002\/14651858.CD006023.pub3-BIB0467|cit467","unstructured":"Salusky IB Regulation of bone formation in renal osteodystrophy www.clinicaltrials.gov\/show\/NCT00560300"},{"key":"10.1002\/14651858.CD006023.pub3-BIB0468|cit468","unstructured":"NCT01968759 Sevelamer in proteinuric CKD www.clinicalTrials.gov\/show\/NCT01968759"},{"key":"10.1002\/14651858.CD006023.pub3-BIB0469|cit469","unstructured":"Gassman JJ The COMBINE Study: the CKD optimal management with BInders and NicotinamidE www.clinicaltrials.gov\/show\/NCT02258074"},{"key":"10.1002\/14651858.CD006023.pub3-BIB0470|cit470","unstructured":"Toussaint ND Pedagogos E IMPROVE: IMpact of Phosphate Reduction On Vascular End-points in chronic kidney disease www.anzctr.org.au\/trial_view aspx?id=335812"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub3-BIB0471|cit471","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s10157-016-1310-8","article-title":"Design and baseline characteristics of the LANDMARK study","volume":"21","author":"Ogata","year":"2017","journal-title":"Clinical & Experimental Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub3-BIB0472|cit472","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1053\/ajkd.1998.v31.pm9531176","article-title":"Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study","volume":"31","author":"Block","year":"1998","journal-title":"American Journal of Kidney Diseases"},{"issue":"8","key":"10.1002\/14651858.CD006023.pub3-BIB0473|cit473","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1097\/01.ASN.0000133041.27682.A2","article-title":"Mineral metabolism, mortality, and morbidity in maintenance hemodialysis","volume":"15","author":"Block","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD006023.pub3-BIB0474|cit474","doi-asserted-by":"crossref","first-page":"e6942","DOI":"10.5867\/medwave.2017.6942","article-title":"Sevelamer versus calcium-based phosphate binders for chronic kidney disease?","volume":"17","author":"Bravo-Soto","year":"2017","journal-title":"Medwave"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub3-BIB0475|cit475","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1053\/jarr.2003.50016","article-title":"Meta-analysis of the effect of sevelamer on phosphorus, calcium, PTH, and serum lipids in dialysis patients","volume":"10","author":"Burke","year":"2003","journal-title":"Advances in Renal Replacement Therapy"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub3-BIB0476|cit476","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/j.1523-1755.2005.00421.x","article-title":"Pathogenesis of vascular calcification in chronic kidney disease","volume":"68","author":"Cozzolino","year":"2005","journal-title":"Kidney International"},{"issue":"7650","key":"10.1002\/14651858.CD006023.pub3-BIB0477|cit477","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD006023.pub3-BIB0478|cit478","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"8","key":"10.1002\/14651858.CD006023.pub3-BIB0479|cit479","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1111\/j.1440-1797.2011.01482.x","article-title":"Impact of non-traditional phosphate binders and cinacalcet on haemodialysis patient biochemistry, pill burden and cost","volume":"16","author":"Gray","year":"2011","journal-title":"Nephrology"},{"issue":"7","key":"10.1002\/14651858.CD006023.pub3-BIB0480|cit480","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1161\/01.CIR.103.7.987","article-title":"Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure","volume":"103","author":"Guerin","year":"2001","journal-title":"Circulation"},{"issue":"7","key":"10.1002\/14651858.CD006023.pub3-BIB0481|cit481","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1681\/ASN.2005010052","article-title":"Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease","volume":"16","author":"Guti\u00e9rrez","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD006023.pub3-BIB0482|cit482","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJMoa0706130","article-title":"Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis","volume":"359","author":"Guti\u00e9rrez","year":"2008","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub3-BIB0483|cit483","first-page":"111","article-title":"The efficacy and safety of sevelamer and lanthanum versus calcium-containing and iron-based binders in treating hyperphosphatemia in patients with chronic kidney disease: a systematic review and meta-analysis","volume":"32","author":"Habbous","year":"2017","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"11","key":"10.1002\/14651858.CD006023.pub3-BIB0484|cit484","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008327.pub2","article-title":"Interventions for metabolic bone disease in children with chronic kidney disease","author":"Hahn","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7414","key":"10.1002\/14651858.CD006023.pub3-BIB0485|cit485","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD006023.pub3-BIB0486|cit486","unstructured":"Higgins JP Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub3-BIB0487|cit487","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/ki.2008.130","article-title":"Hyperphosphatemia of chronic kidney disease","volume":"74","author":"Hruska","year":"2008","journal-title":"Kidney International"},{"issue":"10","key":"10.1002\/14651858.CD006023.pub3-BIB0488|cit488","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1093\/ndt\/gfp350","article-title":"The effects of calcium-based versus non-calcium-based phosphate binders on mortality among patients with chronic kidney disease: a meta-analysis","volume":"24","author":"Jamal","year":"2009","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"9900","key":"10.1002\/14651858.CD006023.pub3-BIB0489|cit489","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/S0140-6736(13)60897-1","article-title":"Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis","volume":"382","author":"Jamal","year":"2013","journal-title":"Lancet"},{"issue":"4 Suppl 3","key":"10.1002\/14651858.CD006023.pub3-BIB0490|cit490","first-page":"70","article-title":"K\/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease","volume":"42","author":"National Kidney Foundation","year":"2003","journal-title":"American Journal of Kidney Diseases"},{"issue":"113","key":"10.1002\/14651858.CD006023.pub3-BIB0491|cit491","first-page":"S1","article-title":"KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD)","volume":"76","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group","journal-title":"Kidney International - Supplement"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub3-BIB0492|cit492","first-page":"1","article-title":"KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2013","journal-title":"Kidney International - Supplement"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub3-BIB0493|cit493","first-page":"1","article-title":"KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)","volume":"7","author":"Kidney Disease: Improving Glogal Outcomes (KDIGO) CKD-MBD Update Work Group","year":"2017","journal-title":"Kidney International - Supplement"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub3-BIB0494|cit494","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1681\/ASN.2010020186","article-title":"The regulation of parathyroid hormone secretion and synthesis","volume":"22","author":"Kumar","year":"2011","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub3-BIB0495|cit495","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/sj.ki.5002009","article-title":"Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease.[Erratum appears in Kidney Int. 2009 Jun;75(11):1237]","volume":"71","author":"Levin","year":"2007","journal-title":"Kidney International"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub3-BIB0496|cit496","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1523-1755.2004.00877.x","article-title":"A systematic review of sevelamer in ESRD and an analysis of its potential economic impact in Canada and the United States","volume":"66","author":"Manns","year":"2004","journal-title":"Kidney International"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub3-BIB0497|cit497","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005015.pub3","article-title":"Interventions for preventing bone disease in kidney transplant recipients","author":"Palmer","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"11","key":"10.1002\/14651858.CD006023.pub3-BIB0498|cit498","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1001\/jama.2011.308","article-title":"Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis","volume":"305","author":"Palmer","year":"2011","journal-title":"JAMA"},{"issue":"5","key":"10.1002\/14651858.CD006023.pub3-BIB0499|cit499","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1053\/j.ajkd.2016.05.015","article-title":"Phosphate-binding agents in adults with CKD: a network meta-analysis of randomized controlled trials.[Erratum appears in Am J Kidney Dis. 2017 Sep;70(3):452; PMID: 28676197]","volume":"68","author":"Palmer","year":"2016","journal-title":"American Journal of Kidney Diseases"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub3-BIB0500|cit500","doi-asserted-by":"crossref","first-page":"232","DOI":"10.2215\/CJN.06800615","article-title":"Sevelamer versus calcium-based binders for treatment of hyperphosphatemia in CKD: a meta-analysis of randomized controlled trials","volume":"11","author":"Patel","year":"2016","journal-title":"Clinical Journal of The American Society of Nephrology: CJASN"},{"issue":"105","key":"10.1002\/14651858.CD006023.pub3-BIB0501|cit501","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1038\/sj.ki.5001997","article-title":"A new era in phosphate binder therapy: what are the options?","author":"Salusky","year":"2006","journal-title":"Kidney International - Supplement"},{"key":"10.1002\/14651858.CD006023.pub3-BIB0502|cit502","unstructured":"Sch\u00fcnemann HJ Oxman AD Higgins JP Vist GE Glasziou P Guyatt GH Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD006023.pub3-BIB0503|cit503","unstructured":"Sch\u00fcnemann HJ Oxman AD Higgins JP Deeks JJ Glasziou P Guyatt GH Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"6","key":"10.1002\/14651858.CD006023.pub3-BIB0504|cit504","doi-asserted-by":"crossref","first-page":"e0156891","DOI":"10.1371\/journal.pone.0156891","article-title":"Comparative effectiveness of phosphate binders in patients with chronic kidney disease: a systematic review and network meta-analysis","volume":"11","author":"Sekercioglu","year":"2016","journal-title":"PLoS ONE (Electronic Resource]"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub3-BIB0505|cit505","doi-asserted-by":"crossref","first-page":"e0171028","DOI":"10.1371\/journal.pone.0171028","article-title":"Effects of different phosphate lowering strategies in patients with CKD on laboratory outcomes: A systematic review and NMA","volume":"12","author":"Sekercioglu","year":"2017","journal-title":"PLoS ONE (Electronic Resource]"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub3-BIB0506|cit506","doi-asserted-by":"crossref","first-page":"119","DOI":"10.5414\/CNP63119","article-title":"Cellular and molecular mechanisms of secondary hyperparathyroidism","volume":"63","author":"Silver","year":"2005","journal-title":"Clinical Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub3-BIB0507|cit507","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1053\/j.ajkd.2007.12.002","article-title":"A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data","volume":"51","author":"Peter","year":"2008","journal-title":"American Journal of Kidney Diseases"},{"issue":"12","key":"10.1002\/14651858.CD006023.pub3-BIB0508|cit508","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.2215\/CJN.04100609","article-title":"Economic evaluation of sevelamer versus calcium-based phosphate binders in hemodialysis patients: a secondary analysis using centers for Medicare & Medicaid services data","volume":"4","author":"Peter","year":"2009","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub3-BIB0509|cit509","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1053\/j.ajkd.2017.09.007","article-title":"Phosphate-binder use in US dialysis patients: prevalence, costs, evidence, and policies","volume":"71","author":"Peter","year":"2018","journal-title":"American Journal of Kidney Diseases"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub3-BIB0510|cit510","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1097\/01.ASN.0000113243.24155.2F","article-title":"Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: evidence for the complexity of the association between mineral metabolism and outcomes","volume":"15","author":"Stevens","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub3-BIB0511|cit511","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1053\/j.ajkd.2008.03.020","article-title":"Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS)","volume":"52","author":"Tentori","year":"2008","journal-title":"American Journal of Kidney Diseases"},{"issue":"10","key":"10.1002\/14651858.CD006023.pub3-BIB0512|cit512","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1093\/ndt\/gfm421","article-title":"Systematic review of the clinical efficacy and safety of sevelamer in dialysis patients","volume":"22","author":"Tonelli","year":"2007","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1002\/14651858.CD006023.pub3-BIB0513|cit513","unstructured":"United States Renal Data System (USRDS) Costs of ESRD www.usrds.org\/2009\/pdf\/V2_11_09.pdf (accessed July 2018)"},{"issue":"7","key":"10.1002\/14651858.CD006023.pub3-BIB0514|cit514","doi-asserted-by":"crossref","first-page":"e0133938","DOI":"10.1371\/journal.pone.0133938","article-title":"New conclusions regarding comparison of sevelamer and calcium-based phosphate binders in coronary-artery calcification for dialysis patients: a meta-analysis of randomized controlled trials","volume":"10","author":"Wang","year":"2015","journal-title":"PLoS ONE (Electronic Resource]"},{"issue":"7644","key":"10.1002\/14651858.CD006023.pub3-BIB0515|cit515","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1136\/bmj.39465.451748.AD","article-title":"Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study","volume":"336","author":"Wood","year":"2008","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub3-BIB0516|cit516","first-page":"c259","article-title":"Meta-analysis comparing sevelamer and calcium-based phosphate binders on cardiovascular calcification in hemodialysis patients","volume":"115","author":"Zhang","year":"2010","journal-title":"Nephron"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub3-BIB0517|cit517","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006023","article-title":"Phosphate binders for preventing and treating bone disease in chronic kidney disease patients","author":"Navaneethan","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub3-BIB0518|cit518","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006023.pub2","article-title":"Phosphate binders for preventing and treating bone disease in chronic kidney disease patients","author":"Navaneethan","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"}],"updated-by":[{"DOI":"10.1002\/14651858.cd006023.pub4","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T00:00:00Z","timestamp":1750982400000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD006023.pub3\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,17]],"date-time":"2021-08-17T14:55:17Z","timestamp":1629212117000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD006023.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Kidney and Transplant Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2018,8,22]]},"references-count":518,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2018,8]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd006023.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,22]]}}}